{
    "items": "164",
    "sentiment_score_definition": "x <= -0.35: Bearish; -0.35 < x <= -0.15: Somewhat-Bearish; -0.15 < x < 0.15: Neutral; 0.15 <= x < 0.35: Somewhat_Bullish; x >= 0.35: Bullish",
    "relevance_score_definition": "0 < x <= 1, with a higher score indicating higher relevance.",
    "feed": [
        {
            "title": "Why Meta Platforms Stock Topped the Market Today",
            "url": "https://www.fool.com/investing/2024/03/06/why-meta-platforms-stock-topped-the-market-today/",
            "time_published": "20240306T234100",
            "authors": [
                "Eric Volkman"
            ],
            "summary": "Investors were happy that the company had a generally uneventful Wednesday.",
            "banner_image": "https://g.foolcdn.com/editorial/images/768361/young-person-and-older-person-gazing-at-a-laptop-screen.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.365926"
                }
            ],
            "overall_sentiment_score": 0.317375,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.163909",
                    "ticker_sentiment_score": "0.113969",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NFLX",
                    "relevance_score": "0.163909",
                    "ticker_sentiment_score": "0.113969",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.465196",
                    "ticker_sentiment_score": "0.447362",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Nektar  ( NKTR )  Begins Phase IIb Study Rezpeg in Alopecia Areata",
            "url": "https://www.zacks.com/stock/news/2236911/nektar-nktr-begins-phase-iib-study-rezpeg-in-alopecia-areata",
            "time_published": "20240306T173300",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "The placebo-controlled, phase IIb study will investigate the efficacy and safety of Nektar's (NKTR) rezpeg in patients with severe to very severe alopecia areata.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/67/1932.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.682689"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": -0.023958,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.276909",
                    "ticker_sentiment_score": "0.046072",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "INDV",
                    "relevance_score": "0.276909",
                    "ticker_sentiment_score": "0.258128",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "VNDA",
                    "relevance_score": "0.445179",
                    "ticker_sentiment_score": "0.176086",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NKTR",
                    "relevance_score": "0.276909",
                    "ticker_sentiment_score": "-0.256197",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                }
            ]
        },
        {
            "title": "Dexcom Pops As It Enters A New CGM Market: Non-Diabetics",
            "url": "https://www.investors.com/news/technology/dexcom-stock-continuous-glucose-monitor-stelo/",
            "time_published": "20240306T152500",
            "authors": [
                "Investor's Business Daily",
                "ALLISON GATLIN"
            ],
            "summary": "Dexcom Stock Pops After FDA Clears Its New Continuous Glucose Monitor Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2023/03/Stock-dexcom-one-04-adobe.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.94762"
                }
            ],
            "overall_sentiment_score": 0.250101,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.107736",
                    "ticker_sentiment_score": "0.2163",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "ABT",
                    "relevance_score": "0.107736",
                    "ticker_sentiment_score": "0.176098",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "DXCM",
                    "relevance_score": "0.457794",
                    "ticker_sentiment_score": "0.179837",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.107736",
                    "ticker_sentiment_score": "0.2163",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "What's Going With Eli Lilly Stock On Wednesday? - Eli Lilly and Co  ( NYSE:LLY ) ",
            "url": "https://www.benzinga.com/general/biotech/24/03/37510490/escalating-demand-for-obesity-drugs-creates-time-sensitive-race-for-eli-lilly-novo-nordisk",
            "time_published": "20240306T143330",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "Eli Lilly LLY is aggressively pursuing collaborations with outsourcing partners to ramp up the production of its obesity drug, Zepbound ( tirzepatide ) , as it inks deals with key players such as National Resilience and BSP Pharmaceuticals for the filling and \"finishing\" of its injector pens.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/mounjaro-medication-for-weight-loss_7.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.042218,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.601928",
                    "ticker_sentiment_score": "-0.035373",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CTLT",
                    "relevance_score": "0.221819",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.327366",
                    "ticker_sentiment_score": "-0.090714",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Is Viking Therapeutics Stock a Better Buy Than Eli Lilly and Novo Nordisk After the Latest Weight-Loss Drug News?",
            "url": "https://www.fool.com/investing/2024/03/06/is-viking-therapeutics-stock-a-better-buy-than-eli/",
            "time_published": "20240306T105000",
            "authors": [
                "Keith Speights"
            ],
            "summary": "A new player in the multibillion-dollar weight-loss drug market could be waiting in the wings.",
            "banner_image": "https://g.foolcdn.com/editorial/images/768024/scientists-smiling-and-shaking-hands.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.360215"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.209691,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.63878",
                    "ticker_sentiment_score": "0.405744",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "VKTX",
                    "relevance_score": "0.398148",
                    "ticker_sentiment_score": "0.207258",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.603465",
                    "ticker_sentiment_score": "0.395508",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Why Dialysis Stocks DaVita, Fresenius Soared On Novo's Ozempic News",
            "url": "https://www.investors.com/news/technology/davita-stock-novo-nordisk-weight-loss-drug-dialysis/",
            "time_published": "20240305T154000",
            "authors": [
                "ALLISON GATLIN",
                "Investor's Business Daily"
            ],
            "summary": "DaVita Stock Soars As Weight-Loss Drug Looks Unlikely To Undermine Dialysis Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2019/11/stock-DaVita-01-shutter.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.413559"
                }
            ],
            "overall_sentiment_score": 0.012189,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.18602",
                    "ticker_sentiment_score": "0.157505",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "FSNUF",
                    "relevance_score": "0.093653",
                    "ticker_sentiment_score": "0.267198",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "DVA",
                    "relevance_score": "0.589793",
                    "ticker_sentiment_score": "0.190103",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.362065",
                    "ticker_sentiment_score": "0.144641",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Prediction: Eli Lilly and Novo Nordisk Stock Could Just be Getting Started. Here's Why",
            "url": "https://www.fool.com/investing/2024/03/05/eli-lilly-and-novo-nordisk-could-just-be-getting/",
            "time_published": "20240305T145300",
            "authors": [
                "Adam Spatacco"
            ],
            "summary": "Eli Lilly and Novo Nordisk dominate the diabetes market thanks to blockbuster medications Mounjaro, Ozempic, and Rybelsus.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F767512%2Fstatistic_id271464_diabetics-prevalence-worldwide-2021-2030-and-2045.png&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                }
            ],
            "overall_sentiment_score": 0.221674,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.41627",
                    "ticker_sentiment_score": "0.367741",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "CTLT",
                    "relevance_score": "0.108958",
                    "ticker_sentiment_score": "0.187892",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.506613",
                    "ticker_sentiment_score": "0.285938",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Better Weight Loss Drug Stock: Viking Therapeutics vs. Eli Lilly",
            "url": "https://www.fool.com/investing/2024/03/05/better-weight-loss-drug-stock-viking-therapeutics/",
            "time_published": "20240305T111500",
            "authors": [
                "Alex Carchidi"
            ],
            "summary": "One is a reigning champion, and the other is a burgeoning contender.",
            "banner_image": "https://g.foolcdn.com/editorial/images/767463/scientists-lab-testing-blood-draw.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.365926"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.650727"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.135374,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.274834",
                    "ticker_sentiment_score": "0.159272",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "VKTX",
                    "relevance_score": "0.230454",
                    "ticker_sentiment_score": "0.152596",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "MS",
                    "relevance_score": "0.046724",
                    "ticker_sentiment_score": "-0.000999",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Jim Cramer Says Nvidia, Eli Lilly, Novo Nordisk Are Not Overvalued: 'Will Be Ready To Buy If This Market Sells Off' - NVIDIA  ( NASDAQ:NVDA ) , Eli Lilly and Co  ( NYSE:LLY ) ",
            "url": "https://www.benzinga.com/markets/equities/24/03/37474512/jim-cramer-says-nvidia-eli-lilly-novo-nordisk-are-not-overvalued-will-be-ready-to-buy-if-this-ma",
            "time_published": "20240305T063337",
            "authors": [
                "Benzinga Neuro"
            ],
            "summary": "CNBC host Jim Cramer advised investors to gear up for a potential market sell-off, asserting that they should be ready to make purchases if undervalued stocks dip.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Jim-Cramer_2.png?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.248444,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.277958",
                    "ticker_sentiment_score": "0.227008",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.277958",
                    "ticker_sentiment_score": "0.264682",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.277958",
                    "ticker_sentiment_score": "0.227008",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Eli Lilly  ( LLY )  Increases Despite Market Slip: Here's What You Need to Know",
            "url": "https://www.zacks.com/stock/news/2235647/eli-lilly-lly-increases-despite-market-slip-heres-what-you-need-to-know",
            "time_published": "20240304T224518",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "In the latest trading session, Eli Lilly (LLY) closed at $792.28, marking a +1.3% move from the previous day.",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default165.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.95493"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.316726"
                }
            ],
            "overall_sentiment_score": 0.199086,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.636698",
                    "ticker_sentiment_score": "0.254963",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Two more stock indexes are on track for records: What that means for the bull market",
            "url": "https://www.marketwatch.com/story/two-more-stock-indexes-are-on-track-for-records-what-that-means-for-the-bull-market-044b8b21",
            "time_published": "20240304T183200",
            "authors": [
                "Joseph Adinolfi"
            ],
            "summary": "Both the S&P 400 midcap Index and an ETF that tracks the S&P 500 equal-weight index appeared poised for record closes on Monday, an indication that more stocks are joining a rally that has been criticized for its dependence on Big Tech.",
            "banner_image": "https://images.mktw.net/im-30026221/social",
            "source": "MarketWatch",
            "category_within_source": "Top Stories",
            "source_domain": "www.marketwatch.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.576289"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.999966"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.25"
                }
            ],
            "overall_sentiment_score": 0.143078,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "MSTR",
                    "relevance_score": "0.078099",
                    "ticker_sentiment_score": "0.079609",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.039096",
                    "ticker_sentiment_score": "0.240434",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.078099",
                    "ticker_sentiment_score": "0.249461",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.078099",
                    "ticker_sentiment_score": "0.249461",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AAPL",
                    "relevance_score": "0.078099",
                    "ticker_sentiment_score": "0.249461",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AVGO",
                    "relevance_score": "0.078099",
                    "ticker_sentiment_score": "0.071764",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BAC",
                    "relevance_score": "0.078099",
                    "ticker_sentiment_score": "0.081062",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SMCI",
                    "relevance_score": "0.078099",
                    "ticker_sentiment_score": "0.079609",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BRK-A",
                    "relevance_score": "0.039096",
                    "ticker_sentiment_score": "0.068776",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "IVZ",
                    "relevance_score": "0.039096",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.078099",
                    "ticker_sentiment_score": "0.249461",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.078099",
                    "ticker_sentiment_score": "0.249461",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.078099",
                    "ticker_sentiment_score": "0.071764",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Eli Lilly and Co Options Trading: A Deep Dive into Market Sentiment - Eli Lilly and Co  ( NYSE:LLY ) ",
            "url": "https://www.benzinga.com/insights/options/24/03/37460353/eli-lilly-and-co-options-trading-a-deep-dive-into-market-sentiment",
            "time_published": "20240304T160205",
            "authors": [
                "Benzinga Insights"
            ],
            "summary": "Financial giants have made a conspicuous bearish move on Eli Lilly and Co. Our analysis of options history for Eli Lilly and Co LLY revealed 80 unusual trades. Delving into the details, we found 35% of traders were bullish, while 65% showed bearish tendencies.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Markets",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.365926"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.028882,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.771557",
                    "ticker_sentiment_score": "0.068128",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WFC",
                    "relevance_score": "0.087185",
                    "ticker_sentiment_score": "-0.096824",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MS",
                    "relevance_score": "0.087185",
                    "ticker_sentiment_score": "-0.021063",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "1 Wall Street Analyst Thinks Eli Lilly Stock Is Going to $1000. Is It a Buy Around $782?",
            "url": "https://www.fool.com/investing/2024/03/04/1-analyst-thinks-eli-lilly-stock-is-going-to-1000/",
            "time_published": "20240304T112500",
            "authors": [
                "Rich Smith"
            ],
            "summary": "There are two big reasons why Eli Lilly stock is as much as 5x more expensive than Pfizer.",
            "banner_image": "https://g.foolcdn.com/editorial/images/767709/origami-dollar-folded-into-an-arrow-pointing-up.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.266143"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.947132"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.107831,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "BAC",
                    "relevance_score": "0.110462",
                    "ticker_sentiment_score": "0.055756",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.733479",
                    "ticker_sentiment_score": "0.171272",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.218817",
                    "ticker_sentiment_score": "-0.083832",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Here's How Much You'd Have If You Invested $10,000 in Eli Lilly Stock When Billionaire George Soros First Bought It",
            "url": "https://www.fool.com/investing/2024/03/04/invested-eli-lilly-stock-george-soros/",
            "time_published": "20240304T104800",
            "authors": [
                "Keith Speights"
            ],
            "summary": "The tricky part would have been to not sell the pharmaceutical giant's shares when Soros did.",
            "banner_image": "https://media.ycharts.com/charts/12df98e3752c74616e6161b640865a2b.png",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.980922"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.177895,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.77688",
                    "ticker_sentiment_score": "0.278347",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "MORN",
                    "relevance_score": "0.060694",
                    "ticker_sentiment_score": "0.244166",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "This Is the Biggest Company Not in the \"Magnificent Seven\" -- but It Deserves to Be",
            "url": "https://www.fool.com/investing/2024/03/04/big-company-not-in-magnificent-seven-lilly/",
            "time_published": "20240304T095500",
            "authors": [
                "James Brumley"
            ],
            "summary": "It's in a distinctly different business than the \"Magnificent Seven\" companies, but it deserves the same attention.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F767518%2F022924-eli-lilly-results.png&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.266143"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.451494"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.25"
                }
            ],
            "overall_sentiment_score": 0.305234,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.46341",
                    "ticker_sentiment_score": "0.414854",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.044801",
                    "ticker_sentiment_score": "0.139985",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.089462",
                    "ticker_sentiment_score": "0.127166",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GS",
                    "relevance_score": "0.044801",
                    "ticker_sentiment_score": "0.071754",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.044801",
                    "ticker_sentiment_score": "0.104019",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Better Blockbuster-Drug Stock: Novo Nordisk vs. Eli Lilly",
            "url": "https://www.fool.com/investing/2024/03/03/blockbuster-drug-stock-novo-nordisk-vs-eli-lilly/",
            "time_published": "20240303T175100",
            "authors": [
                "Alex Carchidi"
            ],
            "summary": "This is a close contest, and it'll go on for at least a few more rounds.",
            "banner_image": "https://g.foolcdn.com/editorial/images/766405/investor-considers-writing-on-glass-wall-while-another-sits-in-the-background.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.294216,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.20537",
                    "ticker_sentiment_score": "0.244637",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.351273",
                    "ticker_sentiment_score": "0.375129",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Better Buy: Eli Lilly vs. Viking Therapeutics",
            "url": "https://www.fool.com/investing/2024/03/03/better-buy-eli-lilly-vs-viking-therapeutics/",
            "time_published": "20240303T143500",
            "authors": [
                "Prosper Junior Bakiny"
            ],
            "summary": "These two biotechs could eventually go head to head in a fast-growing market.",
            "banner_image": "https://g.foolcdn.com/editorial/images/767192/patient-talking-with-a-physician.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "IPO",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.929393"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.818451"
                }
            ],
            "overall_sentiment_score": 0.18215,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.497609",
                    "ticker_sentiment_score": "0.258264",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "VKTX",
                    "relevance_score": "0.457977",
                    "ticker_sentiment_score": "0.156752",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "3 Magnificent Growth Stocks to Buy in March",
            "url": "https://www.fool.com/investing/2024/03/02/3-magnificent-growth-stocks-to-buy-in-march/",
            "time_published": "20240302T143000",
            "authors": [
                "and Prosper Junior Bakiny",
                "David Jagielski",
                "Keith Speights"
            ],
            "summary": "These three stocks have two important common denominators: the same industry and tremendous growth prospects.",
            "banner_image": "https://g.foolcdn.com/editorial/images/767491/happy-woman-because-the-stock-market-went-up.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.413559"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.360215"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.211721,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.262052",
                    "ticker_sentiment_score": "0.24374",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "VRTX",
                    "relevance_score": "0.262052",
                    "ticker_sentiment_score": "0.240059",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "MRNA",
                    "relevance_score": "0.344473",
                    "ticker_sentiment_score": "0.130278",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MS",
                    "relevance_score": "0.044469",
                    "ticker_sentiment_score": "0.153986",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.044469",
                    "ticker_sentiment_score": "0.060995",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Is It Too Late to Buy Eli Lilly Stock Now?",
            "url": "https://www.fool.com/investing/2024/03/02/is-it-too-late-to-buy-eli-lilly-stock-now/",
            "time_published": "20240302T131500",
            "authors": [
                "Adam Spatacco"
            ],
            "summary": "Eli Lilly stock is having a moment, but the company could easily continue soaring.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F766723%2Fa-doctor-writing-a-prescription.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.108179"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.214378"
                }
            ],
            "overall_sentiment_score": 0.250494,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.539306",
                    "ticker_sentiment_score": "0.300425",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.097854",
                    "ticker_sentiment_score": "0.10883",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Market Rally At Highs; Here's What To Do Now",
            "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-nasdaq-hits-high-taiwan-semi-jumps/",
            "time_published": "20240301T215300",
            "authors": [
                "ED CARSON",
                "Investor's Business Daily"
            ],
            "summary": "Dow Jones Futures: Nasdaq Hits Record High, Taiwan Semi Jumps. Here's What To Do Now Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2023/11/Stock-greenishbull-01-adobe.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.769861"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.25"
                }
            ],
            "overall_sentiment_score": 0.192437,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.217346",
                    "ticker_sentiment_score": "0.129721",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.136888",
                    "ticker_sentiment_score": "0.116911",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VKTX",
                    "relevance_score": "0.054983",
                    "ticker_sentiment_score": "0.145853",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AAPL",
                    "relevance_score": "0.082393",
                    "ticker_sentiment_score": "0.047008",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BAC",
                    "relevance_score": "0.027508",
                    "ticker_sentiment_score": "0.135793",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMD",
                    "relevance_score": "0.054983",
                    "ticker_sentiment_score": "0.218934",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.163909",
                    "ticker_sentiment_score": "0.08363",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "UBER",
                    "relevance_score": "0.136888",
                    "ticker_sentiment_score": "0.06972",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "UNH",
                    "relevance_score": "0.054983",
                    "ticker_sentiment_score": "0.013989",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PLTR",
                    "relevance_score": "0.082393",
                    "ticker_sentiment_score": "0.052243",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSM",
                    "relevance_score": "0.082393",
                    "ticker_sentiment_score": "0.079567",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Record-High S&P 500 Propels SPY ETF To $500-Billion Milestone, Nvidia Tops $2 Trillion, Broadcom Surpasses Tesla - SPDR S&P 500  ( ARCA:SPY ) ",
            "url": "https://www.benzinga.com/markets/equities/24/03/37430818/record-high-s-p-500-propels-spy-etf-to-500-billion-milestone-nvidia-tops-2-trillion-broadcom-sur",
            "time_published": "20240301T210512",
            "authors": [
                "Piero Cingari"
            ],
            "summary": "The U.S. stock market continues its unchallenged bull run, with Wall Street notching yet another week of record-breaking highs for the S&P 500 and Nasdaq 100 indices. This ongoing surge demonstrates the remarkable strength of the bullish sentiment, with stocks marking their 16th positive week out ...",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/SP500.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Markets",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.917436"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.294378,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.338582",
                    "ticker_sentiment_score": "0.487477",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.338582",
                    "ticker_sentiment_score": "0.487477",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "AVGO",
                    "relevance_score": "0.338582",
                    "ticker_sentiment_score": "0.487477",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.338582",
                    "ticker_sentiment_score": "0.487477",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Why Is Eli Lilly Stock Trading Higher Today? - Eli Lilly and Co  ( NYSE:LLY ) ",
            "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/03/37430399/eli-lillys-commercial-moat-competitor-landscape-bofa-emphasizes-strength-in-increti",
            "time_published": "20240301T204459",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "BofA Securities says Eli Lilly and Company LLY remains a top choice in Biopharma analysis, boasting a remarkable year-to-date performance of +29% ( compared to the DRG index's +10% ) .",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/mounjaro-medication-for-weight-loss_6.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.360215"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.495866"
                }
            ],
            "overall_sentiment_score": 0.412925,
            "overall_sentiment_label": "Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.597525",
                    "ticker_sentiment_score": "0.545815",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.324495",
                    "ticker_sentiment_score": "0.432372",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "How investors can ride along as a global commodity market shifts away from China",
            "url": "https://www.marketwatch.com/story/heres-how-investors-can-ride-along-as-a-major-global-commodity-market-shifts-away-from-china-2d122885",
            "time_published": "20240301T175200",
            "authors": [
                "Philip van Doorn"
            ],
            "summary": "China has long dominated the world market for rare earth minerals, which are required components of many devices.",
            "banner_image": "https://images.mktw.net/im-99051667?width=700&height=486",
            "source": "MarketWatch",
            "category_within_source": "Top Stories",
            "source_domain": "www.marketwatch.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Blockchain",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.999995"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.650727"
                }
            ],
            "overall_sentiment_score": 0.092941,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.037563",
                    "ticker_sentiment_score": "0.119251",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.075043",
                    "ticker_sentiment_score": "0.124097",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.258351",
                    "ticker_sentiment_score": "0.255928",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AAPL",
                    "relevance_score": "0.112357",
                    "ticker_sentiment_score": "0.088038",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "C",
                    "relevance_score": "0.037563",
                    "ticker_sentiment_score": "-0.022334",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BAC",
                    "relevance_score": "0.037563",
                    "ticker_sentiment_score": "0.047489",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SNOW",
                    "relevance_score": "0.149424",
                    "ticker_sentiment_score": "-0.008163",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.075043",
                    "ticker_sentiment_score": "0.102997",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NYCB",
                    "relevance_score": "0.258351",
                    "ticker_sentiment_score": "-0.136767",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.075043",
                    "ticker_sentiment_score": "0.124097",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VKTX",
                    "relevance_score": "0.112357",
                    "ticker_sentiment_score": "0.164847",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.075043",
                    "ticker_sentiment_score": "0.124097",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.075043",
                    "ticker_sentiment_score": "0.102997",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SBNY",
                    "relevance_score": "0.037563",
                    "ticker_sentiment_score": "-0.068027",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CRYPTO:BTC",
                    "relevance_score": "0.075043",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Rally At Highs After Big Earnings, Inflation Data: Weekly Review",
            "url": "https://www.investors.com/news/stock-market-rally-at-highs-after-big-earnings-inflation-data-weekly-review/",
            "time_published": "20240301T171100",
            "authors": [
                "IBD STAFF",
                "Investor's Business Daily"
            ],
            "summary": "Market Rally At High: Weekly Review Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2017/08/HTI-WALLSTREET-adobe.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Blockchain",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.838487"
                },
                {
                    "topic": "IPO",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.998356"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Real Estate & Construction",
                    "relevance_score": "0.166667"
                }
            ],
            "overall_sentiment_score": 0.072772,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "CELH",
                    "relevance_score": "0.127795",
                    "ticker_sentiment_score": "0.070199",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FRO",
                    "relevance_score": "0.064104",
                    "ticker_sentiment_score": "0.170246",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "FOUR",
                    "relevance_score": "0.042762",
                    "ticker_sentiment_score": "-0.07846",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "HPQ",
                    "relevance_score": "0.064104",
                    "ticker_sentiment_score": "-0.045922",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VEEV",
                    "relevance_score": "0.042762",
                    "ticker_sentiment_score": "0.051869",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ALT",
                    "relevance_score": "0.064104",
                    "ticker_sentiment_score": "0.009016",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AWON",
                    "relevance_score": "0.021388",
                    "ticker_sentiment_score": "-0.032482",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DPZ",
                    "relevance_score": "0.042762",
                    "ticker_sentiment_score": "0.109933",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DTST",
                    "relevance_score": "0.042762",
                    "ticker_sentiment_score": "0.029796",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NTAP",
                    "relevance_score": "0.064104",
                    "ticker_sentiment_score": "0.126281",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VKTX",
                    "relevance_score": "0.0854",
                    "ticker_sentiment_score": "-0.003141",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PSTG",
                    "relevance_score": "0.127795",
                    "ticker_sentiment_score": "0.069585",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BBY",
                    "relevance_score": "0.064104",
                    "ticker_sentiment_score": "-0.061484",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.042762",
                    "ticker_sentiment_score": "0.008818",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DELL",
                    "relevance_score": "0.0854",
                    "ticker_sentiment_score": "0.006503",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MARA",
                    "relevance_score": "0.042762",
                    "ticker_sentiment_score": "0.092845",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ADSK",
                    "relevance_score": "0.042762",
                    "ticker_sentiment_score": "0.043757",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SNOW",
                    "relevance_score": "0.064104",
                    "ticker_sentiment_score": "-0.048304",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMR",
                    "relevance_score": "0.042762",
                    "ticker_sentiment_score": "-0.003994",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MNST",
                    "relevance_score": "0.0854",
                    "ticker_sentiment_score": "0.146294",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WDAY",
                    "relevance_score": "0.106636",
                    "ticker_sentiment_score": "-0.053552",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DMPZF",
                    "relevance_score": "0.021388",
                    "ticker_sentiment_score": "0.10193",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NTNX",
                    "relevance_score": "0.042762",
                    "ticker_sentiment_score": "0.124126",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ZS",
                    "relevance_score": "0.106636",
                    "ticker_sentiment_score": "0.019519",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "HPE",
                    "relevance_score": "0.042762",
                    "ticker_sentiment_score": "-0.228129",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "CRYPTO:BTC",
                    "relevance_score": "0.106636",
                    "ticker_sentiment_score": "0.037225",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "An analyst call on red-hot Broadcom indicates a possible buying opportunity ahead",
            "url": "https://www.cnbc.com/2024/03/01/an-analyst-call-on-red-hot-broadcom-indicates-a-possible-buying-opportunity-ahead.html",
            "time_published": "20240301T164206",
            "authors": [
                "Morgan Chittum"
            ],
            "summary": "The Investing Club holds its \"Morning Meeting\" every weekday at 10:20 a.m. ET.",
            "banner_image": "https://image.cnbcfm.com/api/v1/image/107380684-1709241555094-gettyimages-2040800689-europapress_5784984_dell_technologies_ceo_michael_dell_speak.jpeg?v=1709241804&w=600&h=300&vtcrop=y",
            "source": "CNBC",
            "category_within_source": "Top News",
            "source_domain": "www.cnbc.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.938793"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.451494"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.22537,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "BAC",
                    "relevance_score": "0.181819",
                    "ticker_sentiment_score": "0.142524",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.181819",
                    "ticker_sentiment_score": "0.142524",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AVGO",
                    "relevance_score": "0.354319",
                    "ticker_sentiment_score": "0.237812",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Lilly Stock Could Join The 1,000 Club With $81 Billion In Obesity Sales",
            "url": "https://www.investors.com/news/technology/eli-lilly-stock-price-target-increase-weight-loss-drugs-obesity-treatment/",
            "time_published": "20240301T163500",
            "authors": [
                "ALLISON GATLIN",
                "Investor's Business Daily"
            ],
            "summary": "Eli Lilly Stock And The Road To 1,000: The $81 Billion Weight-Loss Drugs Space Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2020/10/Stock-EliLilly-Lab01-company.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.99999"
                }
            ],
            "overall_sentiment_score": 0.126199,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.803345",
                    "ticker_sentiment_score": "0.271135",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "VKTX",
                    "relevance_score": "0.120733",
                    "ticker_sentiment_score": "0.019112",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "IRWD",
                    "relevance_score": "0.060541",
                    "ticker_sentiment_score": "-0.16103",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "AMGN",
                    "relevance_score": "0.120733",
                    "ticker_sentiment_score": "0.019112",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.180236",
                    "ticker_sentiment_score": "0.087193",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "3 Healthcare Stocks That Have Outperformed Nvidia Since 2022",
            "url": "https://www.fool.com/investing/2024/03/01/3-healthcare-stocks-that-have-outperformed-nvidia/",
            "time_published": "20240301T134500",
            "authors": [
                "David Jagielski"
            ],
            "summary": "The healthcare sector is no slouch when it comes to top-performing growth stocks.",
            "banner_image": "https://g.foolcdn.com/editorial/images/766658/a-couple-of-investors-looking-at-a-series-of-charts.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.503496"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.967645"
                }
            ],
            "overall_sentiment_score": 0.267726,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.293741",
                    "ticker_sentiment_score": "0.260399",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.11983",
                    "ticker_sentiment_score": "0.261673",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "TMDX",
                    "relevance_score": "0.348919",
                    "ticker_sentiment_score": "0.502508",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "VRNA",
                    "relevance_score": "0.236972",
                    "ticker_sentiment_score": "0.100096",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Got $200? 2 Dividend Stocks to Buy and Hold Forever",
            "url": "https://www.fool.com/investing/2024/03/01/got-200-2-dividend-stocks-to-buy-and-hold-forever/",
            "time_published": "20240301T130000",
            "authors": [
                "Marc Rapport"
            ],
            "summary": "Trust these two real estate stocks to be attractively priced and proven performers.",
            "banner_image": "https://media.ycharts.com/charts/62754a6bac71681cde913b644bbc6635.png",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "IPO",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.977154"
                },
                {
                    "topic": "Real Estate & Construction",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.24037,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.060085",
                    "ticker_sentiment_score": "-0.137007",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ARE",
                    "relevance_score": "0.11983",
                    "ticker_sentiment_score": "-0.002366",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MRNA",
                    "relevance_score": "0.060085",
                    "ticker_sentiment_score": "-0.137007",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.060085",
                    "ticker_sentiment_score": "-0.137007",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "O",
                    "relevance_score": "0.40225",
                    "ticker_sentiment_score": "0.120577",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "2 Stocks That Could Turn $1,000 Into $2,500 in 5 Years",
            "url": "https://www.fool.com/investing/2024/03/01/2-stocks-that-could-turn-1000-into-2500-in-5-years/",
            "time_published": "20240301T123100",
            "authors": [
                "Prosper Junior Bakiny"
            ],
            "summary": "It will take a lot, but this goal isn't out of reach for these stocks.",
            "banner_image": "https://g.foolcdn.com/editorial/images/766641/patient-sitting-on-hospital-bed.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.684621"
                }
            ],
            "overall_sentiment_score": 0.223574,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "VKTX",
                    "relevance_score": "0.441059",
                    "ticker_sentiment_score": "0.168395",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "KRYS",
                    "relevance_score": "0.303175",
                    "ticker_sentiment_score": "0.132994",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.051774",
                    "ticker_sentiment_score": "0.052919",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.051774",
                    "ticker_sentiment_score": "0.052919",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.051774",
                    "ticker_sentiment_score": "0.052919",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMGN",
                    "relevance_score": "0.051774",
                    "ticker_sentiment_score": "0.052919",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.051774",
                    "ticker_sentiment_score": "0.052919",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "These 4 Stocks Are the \"Magnificent Seven\" of Healthcare",
            "url": "https://www.fool.com/investing/2024/03/01/these-stocks-are-magnificent-seven-of-healthcare/",
            "time_published": "20240301T065900",
            "authors": [
                "Alex Carchidi"
            ],
            "summary": "Their growth trajectories aren't as meteoric, but they're still notable.",
            "banner_image": "https://media.ycharts.com/charts/13eb85c054da9d0aa6615994f237628d.png",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.77141"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.27987,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.155786",
                    "ticker_sentiment_score": "0.028625",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.052226",
                    "ticker_sentiment_score": "0.154565",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "VRTX",
                    "relevance_score": "0.104228",
                    "ticker_sentiment_score": "0.188971",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.052226",
                    "ticker_sentiment_score": "0.154565",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "ISRG",
                    "relevance_score": "0.104228",
                    "ticker_sentiment_score": "0.083806",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.155786",
                    "ticker_sentiment_score": "0.137514",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Ozempic, Wegovy And Other Weight-Loss Drugs Won't Solve Global Obesity Crisis Affecting 1B People, WHO Warns - Novo Nordisk  ( NYSE:NVO ) , Eli Lilly and Co  ( NYSE:LLY ) ",
            "url": "https://www.benzinga.com/news/24/03/37413349/ozempic-wegovy-other-weight-loss-drugs-wont-solve-global-obesity-crisis-affecting-1b-people-who-warn",
            "time_published": "20240301T060757",
            "authors": [
                "Benzinga Neuro"
            ],
            "summary": "The World Health Organization ( WHO ) has cautioned that the increasing global obesity crisis, which now affects over a billion people, cannot be resolved by the use of obesity medications alone.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Dorset--Uk--May-25-2020--An-Obese-Couple.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "News",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.046192,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "GS",
                    "relevance_score": "0.087824",
                    "ticker_sentiment_score": "0.065924",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.174587",
                    "ticker_sentiment_score": "-0.033773",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Could These 3 Companies Headline a \"Magnificent Seven\" of Biotech Stocks?",
            "url": "https://www.fool.com/investing/2024/02/29/could-these-3-companies-headline-magnificent-seven/",
            "time_published": "20240229T140000",
            "authors": [
                "Prosper Junior Bakiny"
            ],
            "summary": "These stocks meet many of the criteria long-term investors look for.",
            "banner_image": "https://media.ycharts.com/charts/a0139fd0df9b9ac5ba1cc3d6745e3b8b.png",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.360215"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.360215"
                }
            ],
            "overall_sentiment_score": 0.303241,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.442767",
                    "ticker_sentiment_score": "0.443683",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "VRTX",
                    "relevance_score": "0.205807",
                    "ticker_sentiment_score": "0.163124",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.442767",
                    "ticker_sentiment_score": "0.372147",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Viking Therapeutics takes advantage of soaring stock price to issue fresh shares at a discount",
            "url": "https://www.marketwatch.com/story/viking-therapeutics-takes-advantage-of-soaring-stock-price-to-issue-fresh-shares-at-a-discount-5eb2a7fe",
            "time_published": "20240229T125500",
            "authors": [
                "Ciara Linnane"
            ],
            "summary": "Viking Therapeutics has a stock offering starting at $85 - a discount from its Wednesday closing price of $94.50.",
            "banner_image": "https://images.mktw.net/im-454574/social",
            "source": "MarketWatch",
            "category_within_source": "Top Stories",
            "source_domain": "www.marketwatch.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.214378"
                }
            ],
            "overall_sentiment_score": 0.231491,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.181137",
                    "ticker_sentiment_score": "-0.058797",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VKTX",
                    "relevance_score": "0.181137",
                    "ticker_sentiment_score": "0.34081",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "SPOT",
                    "relevance_score": "0.091162",
                    "ticker_sentiment_score": "0.050801",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.181137",
                    "ticker_sentiment_score": "-0.058797",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Viking Therapeutics: A Teachable Moment About Investing for the Long Term",
            "url": "https://www.fool.com/investing/2024/02/29/viking-therapeutics-a-teachable-moment-about-inves/",
            "time_published": "20240229T124500",
            "authors": [
                "George Budwell"
            ],
            "summary": "The biotherapeutics company's weight loss candidate scored a major win this week.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F767179%2Frocket.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "IPO",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.972756"
                }
            ],
            "overall_sentiment_score": 0.03876,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.193207",
                    "ticker_sentiment_score": "0.14684",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VKTX",
                    "relevance_score": "0.129516",
                    "ticker_sentiment_score": "0.098366",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.193207",
                    "ticker_sentiment_score": "0.14684",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.064973",
                    "ticker_sentiment_score": "-0.056334",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Viking Therapeutics Just Soared 120% on Optimism About Its Weight Loss Candidate. Too Late to Buy?",
            "url": "https://www.fool.com/investing/2024/02/29/viking-soared-120-percent-is-it-a-buy/",
            "time_published": "20240229T114200",
            "authors": [
                "Adria Cimino"
            ],
            "summary": "Viking stock surged in the triple digits in one trading session.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F767161%2Fgettyimages-1226994628.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.316726"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.650727"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.149498,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.150278",
                    "ticker_sentiment_score": "0.129045",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VKTX",
                    "relevance_score": "0.100518",
                    "ticker_sentiment_score": "0.058149",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GS",
                    "relevance_score": "0.050359",
                    "ticker_sentiment_score": "0.163047",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.150278",
                    "ticker_sentiment_score": "0.129045",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Is Viking Therapeutics a Buy Now?",
            "url": "https://www.fool.com/investing/2024/02/29/is-viking-therapeutics-a-buy-now/",
            "time_published": "20240229T095300",
            "authors": [
                "Cory Renauer"
            ],
            "summary": "The stock recently jumped more than 100% overnight thanks to surprising results from its anti-obesity candidate.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F767160%2Fbrilliant-scientist-with-tablet-getty.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.962106"
                }
            ],
            "overall_sentiment_score": 0.271915,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "GS",
                    "relevance_score": "0.059785",
                    "ticker_sentiment_score": "0.031994",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.119235",
                    "ticker_sentiment_score": "0.037096",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VKTX",
                    "relevance_score": "0.235823",
                    "ticker_sentiment_score": "0.376788",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Oprah's departure from Weight Watchers' board is the latest bad news for the stock, amid weight-loss-drug frenzy",
            "url": "https://www.marketwatch.com/story/weight-watchers-shares-fall-sharply-after-oprah-winfrey-decides-not-to-stand-for-board-re-election-94b77c0e",
            "time_published": "20240228T223000",
            "authors": [
                "Bill Peters"
            ],
            "summary": "Shares of WW International Inc., better known as Weight Watchers, tumbled after hours on Wednesday, as the weight-loss platform said Oprah Winfrey planned to leave its board and donate her stake in the company after revealing that she used a weight-loss drug.",
            "banner_image": "https://images.mktw.net/im-15938173/social",
            "source": "MarketWatch",
            "category_within_source": "Top Stories",
            "source_domain": "www.marketwatch.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                }
            ],
            "overall_sentiment_score": 0.12256,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.235823",
                    "ticker_sentiment_score": "0.016068",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WW",
                    "relevance_score": "0.158519",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "HIMS",
                    "relevance_score": "0.158519",
                    "ticker_sentiment_score": "0.009963",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Viking Therapeutics' Weight Loss Study Data Outperformed Novo Nordisk, Eli Lilly Studies, Analysts Say - Viking Therapeutics  ( NASDAQ:VKTX ) ",
            "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/02/37369830/viking-therapeutics-weight-loss-study-data-outperformed-novo-nordisk-eli-lilly-stud",
            "time_published": "20240228T170535",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "Viking Therapeutics Inc VKTX recently released top-line results from a successful Phase 2 weight loss trial. Patients receiving VK2735 demonstrated statistically significant reductions in body weight compared with placebo. The San Diego-based company also announced a capital raise of $350 ...",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/weight-loss-shutter2_1.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.19441,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.187463",
                    "ticker_sentiment_score": "0.030048",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VKTX",
                    "relevance_score": "0.277958",
                    "ticker_sentiment_score": "0.23995",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.187463",
                    "ticker_sentiment_score": "0.030048",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "One down one to go - what we learned from TJX's great quarter and hope to hear from Salesforce",
            "url": "https://www.cnbc.com/2024/02/28/tjxs-quarter-delivers-and-what-cramer-hopes-to-hear-from-salesforce.html",
            "time_published": "20240228T162915",
            "authors": [
                "Morgan Chittum"
            ],
            "summary": "The Investing Club holds its \"Morning Meeting\" every weekday at 10:20 a.m. ET.",
            "banner_image": "https://image.cnbcfm.com/api/v1/image/105048046-GettyImages-878554390.jpg?v=1709136479&w=600&h=300&vtcrop=y",
            "source": "CNBC",
            "category_within_source": "Top News",
            "source_domain": "www.cnbc.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.98396"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.682689"
                }
            ],
            "overall_sentiment_score": 0.122912,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.330654",
                    "ticker_sentiment_score": "0.123265",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VKTX",
                    "relevance_score": "0.085022",
                    "ticker_sentiment_score": "0.053508",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TJX",
                    "relevance_score": "0.330654",
                    "ticker_sentiment_score": "0.123265",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Viking Therapeutics' weight-loss drug data makes company takeover target",
            "url": "https://www.marketwatch.com/story/viking-therapeutics-promising-weight-loss-drug-data-makes-the-company-a-takeover-target-5190434e",
            "time_published": "20240228T161800",
            "authors": [
                "Ciara Linnane"
            ],
            "summary": "Viking Therapeutics Inc.'s stock rose another 8% Wednesday to extend its week-to-date gains to 145%, as analysts weighed in on its positive weight-loss drug news with some bullish commentary and said the company has become an attractive takeover target.",
            "banner_image": "https://images.mktw.net/im-520633/social",
            "source": "MarketWatch",
            "category_within_source": "Top Stories",
            "source_domain": "www.marketwatch.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.459462"
                }
            ],
            "overall_sentiment_score": 0.145905,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.186378",
                    "ticker_sentiment_score": "0.071138",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VKTX",
                    "relevance_score": "0.140348",
                    "ticker_sentiment_score": "0.298538",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.093836",
                    "ticker_sentiment_score": "0.164638",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Large US Drug Makers Highlight Indian Market For Their Blockbuster Drugs Including For Weight Loss - Eli Lilly and Co  ( NYSE:LLY ) , Bristol-Myers Squibb  ( NYSE:BMY ) ",
            "url": "https://www.benzinga.com/general/biotech/24/02/37367547/large-us-drug-makers-highlight-indian-market-for-their-blockbuster-drugs-including-for-weight-los",
            "time_published": "20240228T154650",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "Eli Lilly And Co's LLY CEO, David Ricks, shared the pharmaceutical giant's plans to introduce its obesity drug, tirzepatide, in India as early as next year. Tirzepatide, marketed as Mounjaro for diabetes and Zepbound for weight loss in the United States, holds promise for the Indian market.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Ardelyx-ARDX_3.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.16621,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.33446",
                    "ticker_sentiment_score": "0.265542",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.270523",
                    "ticker_sentiment_score": "0.259582",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "BMY",
                    "relevance_score": "0.204647",
                    "ticker_sentiment_score": "-0.017752",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "The Zacks Analyst Blog Highlights Eli Lilly, The Procter & Gamble, Morgan Stanley, AT&T and Medtronic",
            "url": "https://www.zacks.com/stock/news/2233110/the-zacks-analyst-blog-highlights-eli-lilly-the-procter-gamble-morgan-stanley-att-and-medtronic",
            "time_published": "20240228T141200",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Eli Lilly, The Procter & Gamble, Morgan Stanley, AT&T and Medtronic are part of the Zacks top Analyst Blog.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/3d/451.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.684621"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.215939,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.384102",
                    "ticker_sentiment_score": "0.13888",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MSBHF",
                    "relevance_score": "0.079921",
                    "ticker_sentiment_score": "0.287274",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "MDT",
                    "relevance_score": "0.159043",
                    "ticker_sentiment_score": "0.039287",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "T",
                    "relevance_score": "0.079921",
                    "ticker_sentiment_score": "0.030431",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MS",
                    "relevance_score": "0.236588",
                    "ticker_sentiment_score": "0.052852",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PG",
                    "relevance_score": "0.45283",
                    "ticker_sentiment_score": "0.361651",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Jim Cramer Weighs In On Palo Alto, Eli Lilly And Salesforce, Says Price Target Bump For This Stock A 'Red Flag' - Eli Lilly and Co  ( NYSE:LLY ) , Salesforce  ( NYSE:CRM ) ",
            "url": "https://www.benzinga.com/news/earnings/24/02/37356894/jim-cramer-weighs-in-on-palo-alto-eli-lilly-and-salesforce-says-price-target-bump-for-this-stock-a-",
            "time_published": "20240228T085914",
            "authors": [
                "Benzinga Neuro"
            ],
            "summary": "During Tuesday's CNBC Investing Club Morning Meeting, U.S. stocks exhibited mixed performance, prompting a closer look at prevailing market themes. Cybersecurity emerged as a key focus, with Jim Cramer emphasizing heightened threats following a recent breach at UnitedHealth.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/jim-cramer-shutterstock_17.png?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Markets",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.538269"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.070275,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.287762",
                    "ticker_sentiment_score": "-0.06943",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VKTX",
                    "relevance_score": "0.194242",
                    "ticker_sentiment_score": "-0.051147",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "C",
                    "relevance_score": "0.097854",
                    "ticker_sentiment_score": "0.067322",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WFC",
                    "relevance_score": "0.194242",
                    "ticker_sentiment_score": "0.065095",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "UNH",
                    "relevance_score": "0.097854",
                    "ticker_sentiment_score": "-0.147166",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PANW",
                    "relevance_score": "0.287762",
                    "ticker_sentiment_score": "0.285591",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Why Novo Nordisk and Eli Lilly Stocks Slipped Today",
            "url": "https://www.fool.com/investing/2024/02/27/why-novo-nordisk-and-eli-lilly-stocks-slipped-toda/",
            "time_published": "20240227T230100",
            "authors": [
                "Eric Volkman"
            ],
            "summary": "A competitor to Wegovy and Zepbound might appear on pharmacy shelves before long.",
            "banner_image": "https://g.foolcdn.com/editorial/images/767102/medical-professional-with-hand-on-head.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.065764,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.572601",
                    "ticker_sentiment_score": "0.031781",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VKTX",
                    "relevance_score": "0.249106",
                    "ticker_sentiment_score": "0.005675",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.47452",
                    "ticker_sentiment_score": "0.028501",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Stock Market Today: Stocks End Mixed After Disappointing Economic Data",
            "url": "https://www.kiplinger.com/investing/stocks/stock-market-today-stocks-end-mixed-after-disappointing-economic-data",
            "time_published": "20240227T210737",
            "authors": [
                "Karee Venema"
            ],
            "summary": "Tuesday marked another choppy day for stocks as investors looked ahead to this week's key inflation update and the impact it may or may not have on the Fed's plans for interest rates.",
            "banner_image": "https://cdn.mos.cms.futurecdn.net/hbRMDVRhfJobMQLXddLEdj-415-80.jpg",
            "source": "Kiplinger",
            "category_within_source": "n/a",
            "source_domain": "www.kiplinger.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.838487"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Economy - Fiscal",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.538269"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.451494"
                }
            ],
            "overall_sentiment_score": -0.004874,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.125789",
                    "ticker_sentiment_score": "0.061894",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VKTX",
                    "relevance_score": "0.187705",
                    "ticker_sentiment_score": "0.079591",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "M",
                    "relevance_score": "0.125789",
                    "ticker_sentiment_score": "0.107479",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.125789",
                    "ticker_sentiment_score": "0.061894",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Nvidia, Eli Lilly, AMD Enjoy High Equity Valuations: Do Higher Rates Put Them In Peril? - Advanced Micro Devices  ( NASDAQ:AMD ) , Eli Lilly and Co  ( NYSE:LLY ) ",
            "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/02/37346557/are-nvidia-eli-lilly-amds-high-equity-valuations-in-peril-from-higher-rates",
            "time_published": "20240227T203553",
            "authors": [
                "Neil Dennis"
            ],
            "summary": "Higher long-term rates typically matter a lot to equity valuations. However, according to DataTrek, today's mega-cap stocks are likely to weather the current higher rate environment. Nvidia Corporation NVDA has a price-to-earnings ( P/E ) ratio of 65.8 Eli Lilly And Company LLY even higher ...",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/nvidia-chart-shutter2_2.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.576289"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.365926"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": -0.101636,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "AMD",
                    "relevance_score": "0.245339",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.245339",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.245339",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "How Beam, Up 28% Today, Is Planning To Take On Crispr",
            "url": "https://www.investors.com/news/technology/beam-stock-rockets-to-year-high-as-efforts-to-take-on-crispr-deepen/",
            "time_published": "20240227T192800",
            "authors": [
                "Investor's Business Daily",
                "ALLISON GATLIN"
            ],
            "summary": "Beam Stock Rockets To Year High As Efforts To Take On Crispr Deepen Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2022/10/Stock-beamtherapeutics-01-adobe.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.999186"
                }
            ],
            "overall_sentiment_score": 0.12433,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "BEAM",
                    "relevance_score": "0.177584",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.177584",
                    "ticker_sentiment_score": "0.06926",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VRTX",
                    "relevance_score": "0.11894",
                    "ticker_sentiment_score": "0.38104",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "VERV",
                    "relevance_score": "0.11894",
                    "ticker_sentiment_score": "0.055094",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BLUE",
                    "relevance_score": "0.11894",
                    "ticker_sentiment_score": "0.38104",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Top Analyst Reports for Eli Lilly, Procter & Gamble & Morgan Stanley",
            "url": "https://www.zacks.com/research-daily/2232353/top-analyst-reports-for-eli-lilly-procter-gamble-morgan-stanley",
            "time_published": "20240227T163900",
            "authors": [
                "Mark Vickery"
            ],
            "summary": "Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), The Procter & Gamble Company (PG) and Morgan Stanley (MS).",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c8/39674.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.538269"
                }
            ],
            "overall_sentiment_score": 0.274776,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.233556",
                    "ticker_sentiment_score": "0.156541",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "MSBHF",
                    "relevance_score": "0.118064",
                    "ticker_sentiment_score": "0.317945",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "PG",
                    "relevance_score": "0.344074",
                    "ticker_sentiment_score": "0.575696",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Viking Therapeutics Skyrockets On Weight-Loss Drug Trial Results",
            "url": "https://www.investors.com/news/technology/viking-therapeutics-skyrockets-on-weight-loss-drug-trial-results/",
            "time_published": "20240227T125800",
            "authors": [
                "Investor's Business Daily",
                "ED CARSON"
            ],
            "summary": "Viking Therapeutics ( VKTX ) said Tuesday that its weight-loss drug achieved all goals of its phase two study. Viking stock more than doubled in premarket trade. Eli Lilly ( LLY ) and Novo Nordisk ( NVO ) , which already have weight-loss drugs on the market, fell modestly.",
            "banner_image": "https://www.investors.com/wp-content/uploads/2017/12/Stock-biotech-12-adobe.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.796627"
                }
            ],
            "overall_sentiment_score": 0.026041,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.439786",
                    "ticker_sentiment_score": "-0.217522",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "VKTX",
                    "relevance_score": "0.617765",
                    "ticker_sentiment_score": "-0.170661",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.439786",
                    "ticker_sentiment_score": "-0.217522",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                }
            ]
        },
        {
            "title": "Viking Therapeutics' stock doubles after company reports positive results in trial of weight-loss drug",
            "url": "https://www.marketwatch.com/story/viking-therapeutics-stock-soars-61-premarket-after-company-reports-positive-results-in-trial-of-weight-loss-drug-50e81767",
            "time_published": "20240227T122200",
            "authors": [
                "Ciara Linnane"
            ],
            "summary": "Investors cheer what may be a cheap way to play the current weight-loss drug mania.",
            "banner_image": "https://images.mktw.net/im-832731/social",
            "source": "MarketWatch",
            "category_within_source": "Top Stories",
            "source_domain": "www.marketwatch.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.451494"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.266143"
                }
            ],
            "overall_sentiment_score": 0.070779,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.317254",
                    "ticker_sentiment_score": "0.12217",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VKTX",
                    "relevance_score": "0.129866",
                    "ticker_sentiment_score": "0.02259",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.193723",
                    "ticker_sentiment_score": "0.173518",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Warren Buffett's Berkshire Hathaway, Elon Musk's Tesla And Eli Lilly Could Be Next Trillion-Dollar Companies After Nvidia's Rapid Ascension: Jim Cramer - Broadcom  ( NASDAQ:AVGO ) , Eli Lilly and Co  ( NYSE:LLY ) ",
            "url": "https://www.benzinga.com/markets/equities/24/02/37327396/warren-buffetts-berkshire-hathaway-elon-musks-tesla-and-eli-lilly-could-be-next-trillion-dollar-",
            "time_published": "20240227T040558",
            "authors": [
                "Benzinga Neuro"
            ],
            "summary": "CNBC's Jim Cramer has identified three companies that could potentially join the trillion-dollar club, in the wake of Nvidia Corp's NVDA rapid ascension. What Happened: On Monday, Cramer named Eli Lilly and Co LLY, Berkshire Hathaway Inc BRK BRK, and Tesla Inc TSLA as potential candidates for the ...",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Jim-Cramer_0.png?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Markets",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.25"
                }
            ],
            "overall_sentiment_score": 0.221406,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.237358",
                    "ticker_sentiment_score": "0.227172",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.080188",
                    "ticker_sentiment_score": "0.16921",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.519002",
                    "ticker_sentiment_score": "0.212441",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AVGO",
                    "relevance_score": "0.159569",
                    "ticker_sentiment_score": "0.056728",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.237358",
                    "ticker_sentiment_score": "0.131965",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BRK-A",
                    "relevance_score": "0.237358",
                    "ticker_sentiment_score": "0.142234",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Hims & Hers' stock jumps on hopes of a first profitable year, as it floats opportunities in weight loss",
            "url": "https://www.marketwatch.com/story/hims-hers-stock-jumps-on-forecasts-4290103d",
            "time_published": "20240227T005100",
            "authors": [
                "Bill Peters"
            ],
            "summary": "Shares of Hims & Hers Health Inc. rallied after hours on Monday, after the online wellness platform said 2024 would be its first year of positive net income and forecast first-quarter and full-year sales that were above expectations.",
            "banner_image": "https://images.mktw.net/im-30342026/social",
            "source": "MarketWatch",
            "category_within_source": "Top Stories",
            "source_domain": "www.marketwatch.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.95493"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.18338,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.130571",
                    "ticker_sentiment_score": "0.065268",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WW",
                    "relevance_score": "0.194763",
                    "ticker_sentiment_score": "0.084826",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TDOC",
                    "relevance_score": "0.130571",
                    "ticker_sentiment_score": "-0.025719",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "HIMS",
                    "relevance_score": "0.065506",
                    "ticker_sentiment_score": "0.263916",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Another Reason Why Nvidia Is King Of Tech",
            "url": "https://www.investors.com/research/nvidia-nvda-stock-warren-buffett-berkshire-hathaway-sp500-lly-meta-stock/",
            "time_published": "20240226T183200",
            "authors": [
                "KIMBERLEY KOENIG",
                "Investor's Business Daily"
            ],
            "summary": "Nvidia Stock: Another Reason Why It's The King Of Tech Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2017/11/Stock-NVIDIA09-shutter.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.99977"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.838487"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.25"
                }
            ],
            "overall_sentiment_score": 0.219213,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.22861",
                    "ticker_sentiment_score": "0.243106",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.283542",
                    "ticker_sentiment_score": "0.284156",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.337044",
                    "ticker_sentiment_score": "0.331382",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "BRK-A",
                    "relevance_score": "0.115509",
                    "ticker_sentiment_score": "0.068861",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Amgen's Upcoming Catalysts In 2024 Set To Unlock Multi-Billion Dollar Markets, Says Goldman Sachs - Amgen  ( NASDAQ:AMGN ) ",
            "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/02/37318123/amgens-upcoming-catalysts-in-2024-set-to-unlock-multi-billion-dollar-markets-says-g",
            "time_published": "20240226T182533",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "Amgen Inc AMGN is expected to unveil updates on various programs this year, targeting significant markets. Despite concerns about the company's long-term growth amid exclusivity losses, Goldman Sachs notes that Amgen ( Buy rating, $350 price target ) is seen as well-positioned to capitalize on ...",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Autoinjector-with-Amgevita-by-Amgen-Adal.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.137255,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.19117",
                    "ticker_sentiment_score": "0.082069",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GS",
                    "relevance_score": "0.371523",
                    "ticker_sentiment_score": "0.172847",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AMGN",
                    "relevance_score": "0.454714",
                    "ticker_sentiment_score": "0.333285",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.19117",
                    "ticker_sentiment_score": "0.082069",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.19117",
                    "ticker_sentiment_score": "0.082069",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Eli Lilly, Novo Nordisk's Strategies Against New Weight-Loss Drug Competitors - AstraZeneca  ( NASDAQ:AZN ) , Catalent  ( NYSE:CTLT ) ",
            "url": "https://www.benzinga.com/news/earnings/24/02/37315592/eli-lilly-novo-nordisks-strategies-against-new-weight-loss-drug-competitors",
            "time_published": "20240226T163135",
            "authors": [
                "Neil Dennis"
            ],
            "summary": "The race for new drugs to fight obesity and associated diabetes and cardiovascular diseases heated up on Monday after positive results from trials by Zealand Pharma were published, pushing the Danish company's shares 30% higher.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/weight-loss-shutter2.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.744043"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.451494"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.182634,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.5341",
                    "ticker_sentiment_score": "0.262817",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.165031",
                    "ticker_sentiment_score": "-0.009696",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CTLT",
                    "relevance_score": "0.165031",
                    "ticker_sentiment_score": "0.072593",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MS",
                    "relevance_score": "0.082963",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.165031",
                    "ticker_sentiment_score": "0.059846",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.165031",
                    "ticker_sentiment_score": "-0.009696",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Biotech Stocks In A Tizzy As New Weight-Loss Rival Enters The Arena",
            "url": "https://www.investors.com/news/technology/biotech-stocks-diverge-on-new-results-for-weight-loss-drug-in-mash-patients/",
            "time_published": "20240226T155200",
            "authors": [
                "Investor's Business Daily",
                "ALLISON GATLIN"
            ],
            "summary": "Biotech Stocks Diverge On New Results For Weight-Loss Drug In MASH Patients Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2024/02/Stock-Altimmune-01-shutt.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.929393"
                }
            ],
            "overall_sentiment_score": 0.170267,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "VKTX",
                    "relevance_score": "0.115232",
                    "ticker_sentiment_score": "0.472711",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "DSSMY",
                    "relevance_score": "0.057767",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.115232",
                    "ticker_sentiment_score": "-0.059975",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.282886",
                    "ticker_sentiment_score": "0.059661",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MDGL",
                    "relevance_score": "0.115232",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VRTX",
                    "relevance_score": "0.057767",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AKRO",
                    "relevance_score": "0.115232",
                    "ticker_sentiment_score": "-0.013949",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ALT",
                    "relevance_score": "0.172097",
                    "ticker_sentiment_score": "-0.030348",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Here is What to Know Beyond Why Eli Lilly and Company  ( LLY )  is a Trending Stock",
            "url": "https://www.zacks.com/stock/news/2231511/here-is-what-to-know-beyond-why-eli-lilly-and-company-lly-is-a-trending-stock",
            "time_published": "20240226T140014",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default114.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.999999"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.623304"
                }
            ],
            "overall_sentiment_score": 0.256927,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.523044",
                    "ticker_sentiment_score": "0.184155",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Warren Buffett's Berkshire Is On Cusp Of Joining The $1 Trillion Club",
            "url": "https://www.investors.com/news/warren-buffett-stock-berkshire-hathaway-on-cusp-of-1-trillion-market-cap/",
            "time_published": "20240226T123000",
            "authors": [
                "ED CARSON",
                "Investor's Business Daily"
            ],
            "summary": "The trillion-dollar club is largely the preserve of tech titans such as Apple ( AAPL ) and Nvidia ( NVDA ) , with Meta Platforms ( META ) rejoining that level this year. But Warren Buffett's Berkshire Hathaway ( BRKB ) is knocking on the door. Berkshire Hathaway has a $952.75 billion ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2019/05/stock-Buffett-Warren-02-shutter.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.999897"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.451494"
                }
            ],
            "overall_sentiment_score": 0.087538,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "META",
                    "relevance_score": "0.201803",
                    "ticker_sentiment_score": "0.034126",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.329992",
                    "ticker_sentiment_score": "0.034596",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VMW",
                    "relevance_score": "0.067919",
                    "ticker_sentiment_score": "0.081763",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AAPL",
                    "relevance_score": "0.329992",
                    "ticker_sentiment_score": "0.078441",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AVGO",
                    "relevance_score": "0.201803",
                    "ticker_sentiment_score": "0.130867",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.201803",
                    "ticker_sentiment_score": "0.034126",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BRK-A",
                    "relevance_score": "0.449219",
                    "ticker_sentiment_score": "0.224219",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AWON",
                    "relevance_score": "0.067919",
                    "ticker_sentiment_score": "-0.145508",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "UNH",
                    "relevance_score": "0.135347",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.329992",
                    "ticker_sentiment_score": "-0.479514",
                    "ticker_sentiment_label": "Bearish"
                },
                {
                    "ticker": "V",
                    "relevance_score": "0.201803",
                    "ticker_sentiment_score": "0.060578",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.329992",
                    "ticker_sentiment_score": "0.15192",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "WMT",
                    "relevance_score": "0.135347",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "3 Dividend Stocks That Are No-Brainer Buys Right Now",
            "url": "https://www.fool.com/investing/2024/02/24/3-dividend-stocks-that-are-no-brainer-buys-right-n/",
            "time_published": "20240224T120400",
            "authors": [
                "Keith Speights",
                "David Jagielski",
                "and Prosper Junior Bakiny"
            ],
            "summary": "These stocks check off multiple boxes for investors.",
            "banner_image": "https://g.foolcdn.com/editorial/images/766429/man-with-arms-behind-head-looking-at-laptop.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.214378"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.5855"
                }
            ],
            "overall_sentiment_score": 0.279267,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "CBAY",
                    "relevance_score": "0.045224",
                    "ticker_sentiment_score": "0.090452",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.308614",
                    "ticker_sentiment_score": "0.305134",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "CERE",
                    "relevance_score": "0.045224",
                    "ticker_sentiment_score": "0.153058",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "ABBV",
                    "relevance_score": "0.349945",
                    "ticker_sentiment_score": "0.191869",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "GILD",
                    "relevance_score": "0.179454",
                    "ticker_sentiment_score": "0.239576",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Harvard Business Professor on Failing Well",
            "url": "https://www.fool.com/investing/2024/02/24/harvard-business-professor-on-failing-well/",
            "time_published": "20240224T110000",
            "authors": [
                "Motley Fool Staff"
            ],
            "summary": "Why would Eli Lilly put on a failure party?",
            "banner_image": "https://g.foolcdn.com/editorial/images/765894/mfm_18.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.818451"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.029862,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.035138",
                    "ticker_sentiment_score": "0.044716",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "EADSF",
                    "relevance_score": "0.011716",
                    "ticker_sentiment_score": "-0.110904",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BA",
                    "relevance_score": "0.046839",
                    "ticker_sentiment_score": "-0.113812",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "A growing number of stocks are joining the market rally - even as Big Tech still gets the most attention",
            "url": "https://www.marketwatch.com/story/a-growing-number-of-stocks-are-joining-the-market-rally-even-as-big-tech-still-gets-most-of-the-attention-a0231a08",
            "time_published": "20240224T001900",
            "authors": [
                "Joseph Adinolfi"
            ],
            "summary": "Nvidia's blockbuster earnings report helped all 11 of the S&P 500's sectors finish the week in the green for the first time this year.",
            "banner_image": "https://images.mktw.net/im-20169731/social",
            "source": "MarketWatch",
            "category_within_source": "Top Stories",
            "source_domain": "www.marketwatch.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.769861"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.996023"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.310843"
                }
            ],
            "overall_sentiment_score": 0.114012,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.066139",
                    "ticker_sentiment_score": "0.057072",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.033098",
                    "ticker_sentiment_score": "0.147807",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.099066",
                    "ticker_sentiment_score": "0.189099",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "COST",
                    "relevance_score": "0.066139",
                    "ticker_sentiment_score": "0.123246",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Assessing Eli Lilly and Co's Performance Against Competitors In Pharmaceuticals Industry - Eli Lilly and Co  ( NYSE:LLY ) ",
            "url": "https://www.benzinga.com/insights/news/24/02/37287232/assessing-eli-lilly-and-cos-performance-against-competitors-in-pharmaceuticals-industry",
            "time_published": "20240223T160015",
            "authors": [
                "Benzinga Insights"
            ],
            "summary": "Amidst today's fast-paced and highly competitive business environment, it is crucial for investors and industry enthusiasts to conduct comprehensive company evaluations.",
            "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
            "source": "Benzinga",
            "category_within_source": "Trading",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.891286"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.54554"
                }
            ],
            "overall_sentiment_score": 0.207499,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.530253",
                    "ticker_sentiment_score": "0.293242",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "What the Options Market Tells Us About Eli Lilly and Co - Eli Lilly and Co  ( NYSE:LLY ) ",
            "url": "https://www.benzinga.com/insights/options/24/02/37285613/what-the-options-market-tells-us-about-eli-lilly-and-co",
            "time_published": "20240223T150104",
            "authors": [
                "Benzinga Insights"
            ],
            "summary": "Investors with a lot of money to spend have taken a bearish stance on Eli Lilly and Co LLY. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_18.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Markets",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.316726"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": -0.028638,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.790287",
                    "ticker_sentiment_score": "-0.036237",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WFC",
                    "relevance_score": "0.083251",
                    "ticker_sentiment_score": "-0.1043",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MS",
                    "relevance_score": "0.083251",
                    "ticker_sentiment_score": "-0.1043",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "There's A Problem With Today's Obesity Drugs - How These Companies Are Solving It",
            "url": "https://www.investors.com/news/technology/weight-loss-drugs-how-outliers-like-biohaven-regeneron-are-trying-to-squeeze-into-the-obesity-space/",
            "time_published": "20240223T133000",
            "authors": [
                "ALLISON GATLIN",
                "Investor's Business Daily"
            ],
            "summary": "Weight-Loss Drugs: How Outliers Like Biohaven, Regeneron Are Taking On The Muscle Dilemma In The Obesity Space Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2024/02/A1MAIN_weightloss_022324.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.905476"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": -0.012175,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "EVR",
                    "relevance_score": "0.031992",
                    "ticker_sentiment_score": "-0.027602",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BHVN",
                    "relevance_score": "0.063933",
                    "ticker_sentiment_score": "-0.03917",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ARWR",
                    "relevance_score": "0.031992",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CYTK",
                    "relevance_score": "0.015999",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ALUR",
                    "relevance_score": "0.031992",
                    "ticker_sentiment_score": "0.05222",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.031992",
                    "ticker_sentiment_score": "-0.09668",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ALNY",
                    "relevance_score": "0.031992",
                    "ticker_sentiment_score": "-0.061293",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.158938",
                    "ticker_sentiment_score": "0.096962",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VRTX",
                    "relevance_score": "0.031992",
                    "ticker_sentiment_score": "0.092157",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "REGN",
                    "relevance_score": "0.031992",
                    "ticker_sentiment_score": "-0.025591",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMGN",
                    "relevance_score": "0.031992",
                    "ticker_sentiment_score": "0.092157",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Could Eli Lilly Stock Help You Become a Millionaire?",
            "url": "https://www.fool.com/investing/2024/02/23/could-eli-lilly-stock-help-you-become-millionaire/",
            "time_published": "20240223T111100",
            "authors": [
                "David Jagielski"
            ],
            "summary": "Shares of Eli Lilly have risen by roughly 1,190% over the past 10 years.",
            "banner_image": "https://g.foolcdn.com/editorial/images/765978/rich-couple-on-a-boat.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.990999"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.87644"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.30401,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.616842",
                    "ticker_sentiment_score": "0.438468",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "UNH",
                    "relevance_score": "0.069495",
                    "ticker_sentiment_score": "0.214295",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.069495",
                    "ticker_sentiment_score": "0.214295",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Zacks Market Edge Highlights: AAPL, COST, WSM, LLY and HLT",
            "url": "https://www.zacks.com/stock/news/2230610/zacks-market-edge-highlights-aapl-cost-wsm-lly-and-hlt",
            "time_published": "20240223T083500",
            "authors": [
                "Zacks Investment Research"
            ],
            "summary": "AAPL, COST, WSM, LLY and HLT have been highlighted in this Market Edge article.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ad/429.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.999994"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.769861"
                },
                {
                    "topic": "Real Estate & Construction",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.25"
                }
            ],
            "overall_sentiment_score": 0.199463,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.250386",
                    "ticker_sentiment_score": "0.16987",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.042421",
                    "ticker_sentiment_score": "-0.080945",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WSM",
                    "relevance_score": "0.329551",
                    "ticker_sentiment_score": "0.252923",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "HLT",
                    "relevance_score": "0.250386",
                    "ticker_sentiment_score": "0.247198",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AAPL",
                    "relevance_score": "0.367865",
                    "ticker_sentiment_score": "0.171849",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "COST",
                    "relevance_score": "0.250386",
                    "ticker_sentiment_score": "0.352875",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Better Therapeutics Follows Up Wins Including FDA Authorization For AspyreRx In 2023 With Securing FDA Breakthrough Device Designation Targeting Advanced Liver Disease - Eli Lilly  ( NYSE:LLY ) , Better Therapeutics  ( NASDAQ:BTTX ) ",
            "url": "https://www.benzinga.com/partner/biotech/24/02/37268309/better-therapeutics-follows-up-wins-including-fda-authorization-for-aspyrerx-in-2023-with-securin",
            "time_published": "20240222T182518",
            "authors": [
                "Faith Ashmore"
            ],
            "summary": "Researchers, scientists and practitioners in the past few decades have begun to look at healthcare from a more holistic perspective, often challenging traditional medicine. The question on the minds of many is how to integrate holistic medicine into American healthcare - at scale.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Screenshot-2024-02-22-at-11-51-01-PM.png?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.360215"
                }
            ],
            "overall_sentiment_score": 0.282137,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.110717",
                    "ticker_sentiment_score": "0.208398",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "BTTX",
                    "relevance_score": "0.46898",
                    "ticker_sentiment_score": "0.421072",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "SSTK",
                    "relevance_score": "0.055492",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.110717",
                    "ticker_sentiment_score": "0.208398",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "How to Start Stock Investing in Your 50s",
            "url": "https://www.zacks.com/stock/news/2230305/how-to-start-stock-investing-in-your-50s",
            "time_published": "20240222T160200",
            "authors": [
                "Tracey Ryniec"
            ],
            "summary": "Think you're too old to start buying stocks? Think again. Here's some tips.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/75/2558.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.997874"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.769861"
                },
                {
                    "topic": "Real Estate & Construction",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.25"
                }
            ],
            "overall_sentiment_score": 0.186205,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.273297",
                    "ticker_sentiment_score": "0.143963",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.046452",
                    "ticker_sentiment_score": "-0.081777",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WSM",
                    "relevance_score": "0.358798",
                    "ticker_sentiment_score": "0.269233",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "HLT",
                    "relevance_score": "0.273297",
                    "ticker_sentiment_score": "0.264543",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AAPL",
                    "relevance_score": "0.399911",
                    "ticker_sentiment_score": "0.137556",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "COST",
                    "relevance_score": "0.273297",
                    "ticker_sentiment_score": "0.376233",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Here's 1 Pharmaceutical Stock That Looks Unstoppable. Hint: It's Not Novo Nordisk.",
            "url": "https://www.fool.com/investing/2024/02/22/1-pharmaceutical-stock-that-looks-unstoppable/",
            "time_published": "20240222T120000",
            "authors": [
                "Adam Spatacco"
            ],
            "summary": "Eli Lilly is home to many blockbuster drugs including Mounjaro, Jardiance, Zepbound, and more.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F765806%2Fnurse-checking-elderly-patients-blood-pressure-long-term-care-senior-nursing-home-poc.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.360215"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.214378"
                }
            ],
            "overall_sentiment_score": 0.307091,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.6979",
                    "ticker_sentiment_score": "0.507042",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.1172",
                    "ticker_sentiment_score": "0.131827",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Why Eli Lilly Stock Was Feeling Sickly on Wednesday",
            "url": "https://www.fool.com/investing/2024/02/21/why-eli-lilly-stock-was-feeling-sickly-on-wednesda/",
            "time_published": "20240221T225659",
            "authors": [
                "Eric Volkman"
            ],
            "summary": "The company's surging popularity has made it expensive in terms of valuation.",
            "banner_image": "https://g.foolcdn.com/editorial/images/766315/stethescope-atop-us-currency-and-coins.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.87644"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.360215"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.087313,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "BAC",
                    "relevance_score": "0.146916",
                    "ticker_sentiment_score": "0.051227",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.733479",
                    "ticker_sentiment_score": "0.242681",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "MS",
                    "relevance_score": "0.146916",
                    "ticker_sentiment_score": "0.051227",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Eli Lilly Unusual Options Activity - Eli Lilly  ( NYSE:LLY ) ",
            "url": "https://www.benzinga.com/insights/options/24/02/37237588/eli-lilly-unusual-options-activity",
            "time_published": "20240221T150132",
            "authors": [
                "Benzinga Insights"
            ],
            "summary": "Investors with a lot of money to spend have taken a bearish stance on Eli Lilly LLY. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Markets",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.929393"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.050296,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.751437",
                    "ticker_sentiment_score": "0.047479",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WFC",
                    "relevance_score": "0.083541",
                    "ticker_sentiment_score": "-0.131082",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Eli Lilly Has More Than an Ozempic Competitor -- Much More",
            "url": "https://www.fool.com/investing/2024/02/21/eli-lilly-has-more-than-an-ozempic-competitor-much/",
            "time_published": "20240221T113900",
            "authors": [
                "Adam Spatacco"
            ],
            "summary": "Eli Lilly's hottest treatment might be Mounjaro, but the company has a lot more at its disposal.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F765536%2Fdoctors-office-checkup-patient-hospital.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.266143"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.684621"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.220724,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.467176",
                    "ticker_sentiment_score": "0.300582",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "TFC",
                    "relevance_score": "0.049732",
                    "ticker_sentiment_score": "-0.05942",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BCS",
                    "relevance_score": "0.049732",
                    "ticker_sentiment_score": "-0.05942",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MS",
                    "relevance_score": "0.049732",
                    "ticker_sentiment_score": "-0.05942",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.049732",
                    "ticker_sentiment_score": "0.147153",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Abbott Laboratories Stock Gets A Healthy Technical Rating Upgrade",
            "url": "https://www.investors.com/news/abbott-laboratories-stock-gets-a-healthy-technical-rating-upgrade/",
            "time_published": "20240221T080000",
            "authors": [
                "INVESTOR'S BUSINESS DAILY",
                "Investor's Business Daily",
                "JULIE MAK"
            ],
            "summary": "In a welcome move, Abbott Laboratories ( ABT ) stock saw its Relative Strength Rating improve from 67 to 73 on Wednesday. When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.",
            "banner_image": "https://www.investors.com/wp-content/uploads/2017/05/IRU77.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.87644"
                }
            ],
            "overall_sentiment_score": 0.448462,
            "overall_sentiment_label": "Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.268294",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ABT",
                    "relevance_score": "0.769861",
                    "ticker_sentiment_score": "0.685395",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "3 ways a 'Magnificent Seven' stock-market bubble could burst",
            "url": "https://www.marketwatch.com/story/3-ways-a-magnificent-seven-stock-market-bubble-could-burst-df8716d2",
            "time_published": "20240220T173300",
            "authors": [
                "William Watts"
            ],
            "summary": "If the megacap tech rally is indeed a bubble, how might it end?",
            "banner_image": "https://images.mktw.net/im-44847525?width=700&height=560",
            "source": "MarketWatch",
            "category_within_source": "Top Stories",
            "source_domain": "www.marketwatch.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.977154"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.972193"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.101301,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.09347",
                    "ticker_sentiment_score": "0.104925",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.09347",
                    "ticker_sentiment_score": "0.104925",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.09347",
                    "ticker_sentiment_score": "0.104925",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.139804",
                    "ticker_sentiment_score": "0.129381",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AAPL",
                    "relevance_score": "0.139804",
                    "ticker_sentiment_score": "0.123643",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.139804",
                    "ticker_sentiment_score": "0.123643",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.09347",
                    "ticker_sentiment_score": "0.085872",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "5 Best-Performing S&P 500 Stocks Halfway Through Q1",
            "url": "https://www.zacks.com/stock/news/2228329/5-best-performing-sp-500-stocks-halfway-through-q1",
            "time_published": "20240220T130700",
            "authors": [
                "Sweta Killa"
            ],
            "summary": "Nvidia (NVDA), Eli Lilly (LLY), Meta Platforms (META), Uber Technologies (UBER) and Ralph Lauren (RL) are the five best-performing stocks in the S&P 500.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/8a/52792.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.962106"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.999998"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.256075,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.228073",
                    "ticker_sentiment_score": "0.148091",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.282886",
                    "ticker_sentiment_score": "0.135755",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.172097",
                    "ticker_sentiment_score": "0.099699",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "RL",
                    "relevance_score": "0.228073",
                    "ticker_sentiment_score": "0.113019",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "UBER",
                    "relevance_score": "0.228073",
                    "ticker_sentiment_score": "0.141555",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "8 Companies' Profit Is Expected To Outgrow Even Nvidia's This Year",
            "url": "https://www.investors.com/etfs-and-funds/sectors/sp500-companies-profit-is-expected-to-outgrow-even-nvidia-this-year/",
            "time_published": "20240220T130000",
            "authors": [
                "Investor's Business Daily",
                "MATT KRANTZ"
            ],
            "summary": "Investors are understandably jazzed about Nvidia's upcoming earnings report for last year. Growth should be impressive. But analysts think a surprisingly large number of companies will grow even faster this year.",
            "banner_image": "https://www.investors.com/wp-content/uploads/2016/11/it01-chips-111616-adobe.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.576289"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.409819,
            "overall_sentiment_label": "Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.460808",
                    "ticker_sentiment_score": "0.477789",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.139265",
                    "ticker_sentiment_score": "0.388141",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "SKXJF",
                    "relevance_score": "0.0699",
                    "ticker_sentiment_score": "0.012243",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SPGI",
                    "relevance_score": "0.0699",
                    "ticker_sentiment_score": "0.15583",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "DSKYF",
                    "relevance_score": "0.0699",
                    "ticker_sentiment_score": "0.012243",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "RXDX",
                    "relevance_score": "0.0699",
                    "ticker_sentiment_score": "0.012243",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSN",
                    "relevance_score": "0.27432",
                    "ticker_sentiment_score": "0.271547",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "3 Magnificent Growth Stocks to Buy Right Now",
            "url": "https://www.fool.com/investing/2024/02/19/3-magnificent-growth-stocks-to-buy-right-now/",
            "time_published": "20240219T151500",
            "authors": [
                "Keith Speights",
                "and Prosper Junior Bakiny",
                "David Jagielski"
            ],
            "summary": "These stocks share at least two common denominators: a biopharmaceutical focus and great long-term prospects.",
            "banner_image": "https://g.foolcdn.com/editorial/images/765520/happy-stock-investor-holding-smartphone.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.947132"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.999365"
                }
            ],
            "overall_sentiment_score": 0.264978,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.27676",
                    "ticker_sentiment_score": "0.342352",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "VRTX",
                    "relevance_score": "0.160365",
                    "ticker_sentiment_score": "0.311688",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "CERE",
                    "relevance_score": "0.040348",
                    "ticker_sentiment_score": "0.044696",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ABBV",
                    "relevance_score": "0.387075",
                    "ticker_sentiment_score": "0.271117",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Where Will Eli Lilly Be in 5 Years?",
            "url": "https://www.fool.com/investing/2024/02/18/where-will-eli-lilly-be-in-5-years/",
            "time_published": "20240218T064500",
            "authors": [
                "Prosper Junior Bakiny"
            ],
            "summary": "The stock will still be crushing the market in all likelihood.",
            "banner_image": "https://g.foolcdn.com/editorial/images/765320/patient-taking-medicine.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.684621"
                }
            ],
            "overall_sentiment_score": 0.252692,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.377958",
                    "ticker_sentiment_score": "0.149182",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VKTX",
                    "relevance_score": "0.056143",
                    "ticker_sentiment_score": "0.086016",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.056143",
                    "ticker_sentiment_score": "0.086016",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.056143",
                    "ticker_sentiment_score": "0.086016",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Warren Buffett's Empire Nears Trillion-dollar Club As Class A Shares Hit Above $600,000 - Occidental Petroleum  ( NYSE:OXY ) , Eli Lilly  ( NYSE:LLY ) ",
            "url": "https://www.benzinga.com/news/24/02/37193641/warren-buffetts-empire-nears-trillion-dollar-club-as-class-a-shares-hit-above-600-000",
            "time_published": "20240217T182642",
            "authors": [
                "Bibhu Pattnaik"
            ],
            "summary": "This week, Berkshire Hathaway ( NYSE: BRK-A ) achieved a historic milestone as its Class A shares closed above $600,000 for the first time. The surge in share price brings Warren Buffett's iconic conglomerate closer to the coveted $1 trillion market valuation, a feat not yet achieved by any ...",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/02/17/shutterstock_353934110.jpg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Markets",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.266143"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.223416,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.269776",
                    "ticker_sentiment_score": "0.252954",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "OXY",
                    "relevance_score": "0.269776",
                    "ticker_sentiment_score": "0.232025",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "BRK-A",
                    "relevance_score": "0.509589",
                    "ticker_sentiment_score": "0.168757",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Will Weight-Loss, Diabetes Drugs Drive LLY Stock Into $1 Trillion Club?",
            "url": "https://www.investors.com/news/technology/will-weight-loss-diabetes-drugs-drive-lly-stock-into-1-trillion-club/",
            "time_published": "20240216T182700",
            "authors": [
                "REINHARDT KRAUSE",
                "Investor's Business Daily"
            ],
            "summary": "Eli Lilly's ( LLY ) one-two punch of weight-loss and diabetes treatments Zepbound and Mounjaro should drive the biopharma stock higher, said a Morgan Stanley analyst who raised his price target on LLY stock.",
            "banner_image": "https://www.investors.com/wp-content/uploads/2020/10/Stock-EliLilly-03-shutt.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.99793"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.25"
                }
            ],
            "overall_sentiment_score": 0.141259,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.895969",
                    "ticker_sentiment_score": "0.123305",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.232439",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.342487",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.232439",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AAPL",
                    "relevance_score": "0.232439",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MS",
                    "relevance_score": "0.232439",
                    "ticker_sentiment_score": "-0.0608",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "One of our financial stocks hit a new high: Here's why we're eyeing a small trade",
            "url": "https://www.cnbc.com/2024/02/16/one-of-our-financial-stocks-hit-a-new-high-why-were-eyeing-a-trade.html",
            "time_published": "20240216T163839",
            "authors": [
                "Morgan Chittum"
            ],
            "summary": "The Investing Club holds its \"Morning Meeting\" every weekday at 10:20 a.m. ET.",
            "banner_image": "https://image.cnbcfm.com/api/v1/image/107374842-17080976861708097678-33359188627-1080pnbcnews.jpg?v=1708097685&w=600&h=300&vtcrop=y",
            "source": "CNBC",
            "category_within_source": "Top News",
            "source_domain": "www.cnbc.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.682689"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.98396"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.204173,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.260189",
                    "ticker_sentiment_score": "0.170304",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "WFC",
                    "relevance_score": "0.260189",
                    "ticker_sentiment_score": "0.170304",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "MS",
                    "relevance_score": "0.088147",
                    "ticker_sentiment_score": "0.09059",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "What The Future Holds For Google's 'Other Bets'",
            "url": "https://www.investors.com/news/technology/other-bets-x-moonshots-future-google-stock/",
            "time_published": "20240216T154800",
            "authors": [
                "Investor's Business Daily",
                "REINHARDT KRAUSE"
            ],
            "summary": "Other Bets And X Moonshots Key Google Stock's Future Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2024/02/wGoog_2c201924.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "IPO",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.999999"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.998333"
                },
                {
                    "topic": "Mergers & Acquisitions",
                    "relevance_score": "0.538269"
                }
            ],
            "overall_sentiment_score": 0.159278,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "BLK",
                    "relevance_score": "0.015149",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.647825",
                    "ticker_sentiment_score": "0.257439",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.045425",
                    "ticker_sentiment_score": "-0.050985",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.030292",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GM",
                    "relevance_score": "0.030292",
                    "ticker_sentiment_score": "-0.035944",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MS",
                    "relevance_score": "0.030292",
                    "ticker_sentiment_score": "0.050832",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CVGI",
                    "relevance_score": "0.015149",
                    "ticker_sentiment_score": "0.147619",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ABBV",
                    "relevance_score": "0.015149",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.045425",
                    "ticker_sentiment_score": "-0.050985",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.030292",
                    "ticker_sentiment_score": "0.081926",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VWAGY",
                    "relevance_score": "0.015149",
                    "ticker_sentiment_score": "-0.032837",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.045425",
                    "ticker_sentiment_score": "0.116286",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CCZ",
                    "relevance_score": "0.015149",
                    "ticker_sentiment_score": "0.074076",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "UBER",
                    "relevance_score": "0.030292",
                    "ticker_sentiment_score": "0.034053",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMZN",
                    "relevance_score": "0.030292",
                    "ticker_sentiment_score": "0.025574",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "The Zacks Analyst Blog Highlights Mastercard, SAP, CrowdStrike, Eli Lilly and AMETEK",
            "url": "https://www.zacks.com/stock/news/2227385/the-zacks-analyst-blog-highlights-mastercard-sap-crowdstrike-eli-lilly-and-ametek",
            "time_published": "20240216T140500",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Mastercard, SAP, CrowdStrike, Eli Lilly and AMETEK are part of the Zacks top Analyst Blog.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/15/497.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.222237,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.151064",
                    "ticker_sentiment_score": "0.039317",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AME",
                    "relevance_score": "0.151064",
                    "ticker_sentiment_score": "0.039317",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CRWD",
                    "relevance_score": "0.296761",
                    "ticker_sentiment_score": "0.172051",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "SAP",
                    "relevance_score": "0.495015",
                    "ticker_sentiment_score": "0.268534",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "MA",
                    "relevance_score": "0.151064",
                    "ticker_sentiment_score": "0.039317",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Time To Revisit Amphastar As It Calms After A Plunge",
            "url": "https://www.investors.com/stock-lists/sector-leaders/drug-stock-time-to-revisit-amphastar-as-it-settles-after-a-plunge/",
            "time_published": "20240216T130000",
            "authors": [
                "KIMBERLEY KOENIG",
                "Investor's Business Daily"
            ],
            "summary": "Drug stock Amphastar Pharmaceuticals ( AMPH ) has formed a cup base and settled down after a steep sell-off in January. Now, as an IBD Sector Leader, Amphastar stock is about 18% off its all-time high. Amphastar develops injectable, inhalation and intranasal medical and insulin products.",
            "banner_image": "https://www.investors.com/wp-content/uploads/2023/06/Stock-amphastarpharma-01-shutt.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.999365"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.996675"
                }
            ],
            "overall_sentiment_score": 0.162205,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.173333",
                    "ticker_sentiment_score": "0.137582",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.087185",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMPH",
                    "relevance_score": "0.173333",
                    "ticker_sentiment_score": "-0.084832",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "What's Going On Eli Lilly Stock Thursday? - Eli Lilly  ( NYSE:LLY ) ",
            "url": "https://www.benzinga.com/general/biotech/24/02/37160096/uk-becomes-first-major-market-for-eli-lillys-mounjaro-prefilled-pen-for-tackling-obesity",
            "time_published": "20240215T150938",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "Pharmaceutical giant Eli Lilly And Co LLY is set to launch its highly-anticipated obesity drug, Mounjaro ( tirzepatide ) , in Britain this week, making the U.K. the fourth European country to introduce the famed medication.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Basra--Iraq---July-9--2023-Photo-Of-Moun.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.365926"
                }
            ],
            "overall_sentiment_score": 0.187575,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.280615",
                    "ticker_sentiment_score": "0.121513",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.142565",
                    "ticker_sentiment_score": "-0.012856",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "What's Gaining Popularity Among US Teens Battling Obesity? Novo Nordisk's Weight Loss Drug Wegovy - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/general/biotech/24/02/37157967/whats-gaining-popularity-among-us-teens-battling-obesity-novo-nordisks-weight-loss-drug-wegovy",
            "time_published": "20240215T140535",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "A growing number of U.S. adolescents, facing record rates of pediatric obesity, are reportedly turning to Novo Nordisk A/S's NVO weight-loss drug Wegovy ( semaglutide ) . The update comes when the Danish drugmaker is already struggling to meet the demand from adult patients.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Doctor-Measuring-Obese-Man-Waist-Body-Fa.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.030964,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.211191",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.407844",
                    "ticker_sentiment_score": "0.201435",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "CRYPTO:KMD",
                    "relevance_score": "0.106541",
                    "ticker_sentiment_score": "0.15199",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Nearly Half Of S&P 500 Stocks Trade Below 50-Day Moving Average: Which One Is The Cheapest? - Air Products & Chemicals  ( NYSE:APD ) , Archer-Daniels Midland  ( NYSE:ADM ) ",
            "url": "https://www.benzinga.com/markets/equities/24/02/37133520/nearly-half-of-s-p-500-stocks-trade-below-50-day-moving-average-which-one-is-the-cheapest",
            "time_published": "20240214T174915",
            "authors": [
                "Piero Cingari"
            ],
            "summary": "As the S&P 500 index continues to hover near the 5,000-point threshold, not far from its all-time highs, the remarkable surge of over 20% since late October levels created a stark divide with many corporations failing to join the market rally.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/SP500-Shutterstock.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Trading",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.214378"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.25"
                }
            ],
            "overall_sentiment_score": 0.1086,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "META",
                    "relevance_score": "0.202366",
                    "ticker_sentiment_score": "0.337798",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.202366",
                    "ticker_sentiment_score": "0.337798",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.299478",
                    "ticker_sentiment_score": "0.132281",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MKTX",
                    "relevance_score": "0.202366",
                    "ticker_sentiment_score": "0.07476",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.202366",
                    "ticker_sentiment_score": "0.337798",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "ADM",
                    "relevance_score": "0.202366",
                    "ticker_sentiment_score": "0.07476",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "RL",
                    "relevance_score": "0.202366",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CHTR",
                    "relevance_score": "0.202366",
                    "ticker_sentiment_score": "0.07476",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "UBER",
                    "relevance_score": "0.202366",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BA",
                    "relevance_score": "0.202366",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "What's Going On With Eli Lilly Stock Wednesday? - Eli Lilly  ( NYSE:LLY ) ",
            "url": "https://www.benzinga.com/general/biotech/24/02/37129173/whats-going-on-with-eli-lilly-stock-wednesday",
            "time_published": "20240214T153513",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "Year-to-date, Eli Lilly And Company's LLY shares have gained almost 25%, with its enterprise value surpassing $700 billion, according to data from Benzinga Pro. The shares are trading with a session volume of $13.895K, compared to an average volume of 3.156 million.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/mounjaro-medication-for-weight-loss_5.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.684621"
                }
            ],
            "overall_sentiment_score": 0.211575,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.628066",
                    "ticker_sentiment_score": "0.353114",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "3 Perfect Stocks to Buy This Valentine's Day",
            "url": "https://www.fool.com/investing/2024/02/14/3-perfect-stocks-to-buy-this-valentines-day/",
            "time_published": "20240214T105000",
            "authors": [
                "Keith Speights"
            ],
            "summary": "These stocks have sweet long-term prospects.",
            "banner_image": "https://g.foolcdn.com/editorial/images/765046/flowers.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.796627"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.289897,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.252987",
                    "ticker_sentiment_score": "0.252645",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "MS",
                    "relevance_score": "0.064276",
                    "ticker_sentiment_score": "-0.057031",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "HSY",
                    "relevance_score": "0.371523",
                    "ticker_sentiment_score": "0.207879",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Amgen Takes Aim at Novo Nordisk and Eli Lilly, but Is the Stock a Buy?",
            "url": "https://www.fool.com/investing/2024/02/14/amgen-takes-aim-at-novo-nordisk-and-eli-lilly-but/",
            "time_published": "20240214T075900",
            "authors": [
                "Alex Carchidi"
            ],
            "summary": "It faces both clinical and competitive barriers, but they might not matter.",
            "banner_image": "https://g.foolcdn.com/editorial/images/764673/lab-worker-women-in-stem-science-research.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.796627"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.538269"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.190769,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.185662",
                    "ticker_sentiment_score": "0.188728",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AMGN",
                    "relevance_score": "0.230892",
                    "ticker_sentiment_score": "0.215529",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "MS",
                    "relevance_score": "0.046816",
                    "ticker_sentiment_score": "0.062609",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.230892",
                    "ticker_sentiment_score": "0.185687",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Here's why we would be considering buying more Eli Lilly shares if they were down Tuesday",
            "url": "https://www.cnbc.com/2024/02/13/why-we-would-be-considering-buying-more-eli-lilly-shares-if-they-were-down.html",
            "time_published": "20240213T171555",
            "authors": [
                "Morgan Chittum"
            ],
            "summary": "The Investing Club holds its \"Morning Meeting\" every weekday at 10:20 a.m. ET.",
            "banner_image": "https://image.cnbcfm.com/api/v1/image/107372911-17078386721707838668-33318611669-1080pnbcnews.jpg?v=1707838672&w=600&h=300&vtcrop=y",
            "source": "CNBC",
            "category_within_source": "Top News",
            "source_domain": "www.cnbc.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.576289"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.967645"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.451494"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.306676,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.216215",
                    "ticker_sentiment_score": "0.223262",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.072876",
                    "ticker_sentiment_score": "0.134232",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.072876",
                    "ticker_sentiment_score": "0.134232",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PANW",
                    "relevance_score": "0.145145",
                    "ticker_sentiment_score": "0.169681",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "If You Invested $1000 In This Stock 5 Years Ago, You Would Have $6,000 Today - Eli Lilly  ( NYSE:LLY ) ",
            "url": "https://www.benzinga.com/insights/news/24/02/37099915/if-you-invested-1000-in-this-stock-5-years-ago-you-would-have-6-000-today",
            "time_published": "20240213T170033",
            "authors": [
                "Benzinga Insights"
            ],
            "summary": "Eli Lilly LLY has outperformed the market over the past 5 years by 31.12% on an annualized basis producing an average annual return of 43.4%. Currently, Eli Lilly has a market capitalization of $703.02 billion.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/valuestock_image_3.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Trading",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.158543,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.980595",
                    "ticker_sentiment_score": "0.375984",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Incyte's  ( INCY )  Q4 Earnings & Revenues Fall Shy of Estimates",
            "url": "https://www.zacks.com/stock/news/2225655/incytes-incy-q4-earnings-revenues-fall-shy-of-estimates",
            "time_published": "20240213T163700",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Incyte's (INCY) fourth-quarter 2023 earnings and revenues miss estimates. Quarterly revenues cross the $1 billion mark for the first time on the continued growth of Jakafi and the strong launch of Opzelura.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/5d/2633.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.857896"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.129819,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.18046",
                    "ticker_sentiment_score": "0.094203",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "INCY",
                    "relevance_score": "0.607733",
                    "ticker_sentiment_score": "0.117481",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MOR",
                    "relevance_score": "0.045482",
                    "ticker_sentiment_score": "0.156125",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "SNDX",
                    "relevance_score": "0.135857",
                    "ticker_sentiment_score": "-0.021199",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Eli Lilly and Company  ( LLY )  is Attracting Investor Attention: Here is What You Should Know",
            "url": "https://www.zacks.com/stock/news/2225357/eli-lilly-and-company-lly-is-attracting-investor-attention-here-is-what-you-should-know",
            "time_published": "20240213T140012",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default8.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.999999"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.5855"
                }
            ],
            "overall_sentiment_score": 0.250252,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.522096",
                    "ticker_sentiment_score": "0.180854",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Biogen's quarterly results miss expectations amid slow launch of Alzheimer's treatment",
            "url": "https://www.marketwatch.com/story/biogens-quarterly-results-miss-expectations-amid-slow-launch-of-alzheimers-treatment-2d5edeaf",
            "time_published": "20240213T122100",
            "authors": [
                "Eleanor Laise"
            ],
            "summary": "Biogen on Tuesday reported fourth-quarter results that fell short of Wall Street expectations as uptake of its newer drugs failed to offset declining multiple-sclerosis product sales.",
            "banner_image": "https://images.mktw.net/im-31052601/social",
            "source": "MarketWatch",
            "category_within_source": "Top Stories",
            "source_domain": "www.marketwatch.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.988787"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.069737,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.151064",
                    "ticker_sentiment_score": "0.196613",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "ESALF",
                    "relevance_score": "0.224903",
                    "ticker_sentiment_score": "0.108138",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BIIB",
                    "relevance_score": "0.608634",
                    "ticker_sentiment_score": "-0.046896",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Should You Invest in the iShares U.S. Pharmaceuticals ETF  ( IHE ) ?",
            "url": "https://www.zacks.com/stock/news/2225205/should-you-invest-in-the-ishares-us-pharmaceuticals-etf-ihe",
            "time_published": "20240213T112007",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Sector ETF report for ...",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default7.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.215642,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "BLK",
                    "relevance_score": "0.068306",
                    "ticker_sentiment_score": "0.032068",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.136113",
                    "ticker_sentiment_score": "0.064698",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ZTS",
                    "relevance_score": "0.136113",
                    "ticker_sentiment_score": "0.064698",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "IVZ",
                    "relevance_score": "0.136113",
                    "ticker_sentiment_score": "0.044001",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.136113",
                    "ticker_sentiment_score": "0.064698",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Should You Invest in the Fidelity MSCI Health Care Index ETF  ( FHLC ) ?",
            "url": "https://www.zacks.com/stock/news/2225206/should-you-invest-in-the-fidelity-msci-health-care-index-etf-fhlc",
            "time_published": "20240213T112007",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Sector ETF report for ...",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default195.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.331073,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.130217",
                    "ticker_sentiment_score": "0.050334",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "UNH",
                    "relevance_score": "0.130217",
                    "ticker_sentiment_score": "0.050334",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.130217",
                    "ticker_sentiment_score": "0.050334",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Move Aside, Eli Lilly and Novo Nordisk. Wall Street Thinks This Stock Will Be a Bigger Winner Over the Next 12 Months.",
            "url": "https://www.fool.com/investing/2024/02/13/move-aside-eli-lilly-and-novo-nordisk-wall-street/",
            "time_published": "20240213T105000",
            "authors": [
                "Keith Speights"
            ],
            "summary": "There's more for investors to get excited about in the biopharma world than just weight-loss drugs.",
            "banner_image": "https://g.foolcdn.com/editorial/images/764848/scientists-happy.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.576289"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.503496"
                }
            ],
            "overall_sentiment_score": 0.29916,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.570165",
                    "ticker_sentiment_score": "0.488445",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.570165",
                    "ticker_sentiment_score": "0.479945",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.472338",
                    "ticker_sentiment_score": "0.427854",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Jim Cramer Warns Weight Loss Drugs Ozempic, Wegovy And Others Could Impact Food Stocks: 'That Day Will Come' - Eli Lilly  ( NYSE:LLY ) , PepsiCo  ( NASDAQ:PEP ) ",
            "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/02/37086294/jim-cramer-warns-weight-loss-drugs-ozempic-wegovy-and-others-could-impact-food-stoc",
            "time_published": "20240213T064658",
            "authors": [
                "Benzinga Neuro"
            ],
            "summary": "Jim Cramer, the host of CNBC's \"Mad Money,\" has issued a warning to investors about the potential impact of weight loss drugs, such as Ozempic and Wegovy, on the food and beverage industry.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/jim-cramer-shutterstock_11.png?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Markets",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": -0.057754,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.203215",
                    "ticker_sentiment_score": "0.056768",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PEP",
                    "relevance_score": "0.203215",
                    "ticker_sentiment_score": "-0.171236",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                }
            ]
        },
        {
            "title": "Eli Lilly's Weight Loss Drug Tripeptide Is Expanding Market Share, Analyst Outlines What Lies Ahead - Eli Lilly  ( NYSE:LLY ) ",
            "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/02/37077761/eli-lillys-weight-loss-drug-tripeptide-is-expanding-market-share-analyst-outline-wh",
            "time_published": "20240212T195417",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "In support of expectations for Eli Lilly And Company's LLY tripeptide, BMO Capital Markets is tracking weekly Mounjaro, Zepbound, GLP-1 category TRx ( total prescriptions ) , and NRx ( new prescriptions ) . The analyst models $12.78 billion for the fiscal year 2024 tripeptide revenues.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/mounjaro-medication-for-weight-loss_4.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.328248,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.360752",
                    "ticker_sentiment_score": "0.23962",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "A Look at Pharma ETFs After Q4 Earnings",
            "url": "https://www.zacks.com/stock/news/2224986/a-look-at-pharma-etfs-after-q4-earnings",
            "time_published": "20240212T175900",
            "authors": [
                "Sweta Killa"
            ],
            "summary": "The fourth-quarter results of the healthcare sector have been unimpressive, with earnings of companies that have reported so far down 17.7% despite 7% revenue growth. However, many industry bigwigs reported solid results, with some beating on earnings or revenues or both.",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default282.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.999996"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.054971,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.082251",
                    "ticker_sentiment_score": "0.071368",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "IVZ",
                    "relevance_score": "0.123104",
                    "ticker_sentiment_score": "0.058563",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.082251",
                    "ticker_sentiment_score": "-0.003144",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.123104",
                    "ticker_sentiment_score": "0.110586",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "2 Value Stocks With Monster Yields",
            "url": "https://www.fool.com/investing/2024/02/12/2-value-stocks-with-monster-yields/",
            "time_published": "20240212T141500",
            "authors": [
                "George Budwell"
            ],
            "summary": "These two low-priced large-cap stocks sport ginormous yields.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F764890%2Fvalue-vs-price.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.451494"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.15026,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.056275",
                    "ticker_sentiment_score": "0.088091",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "T",
                    "relevance_score": "0.378777",
                    "ticker_sentiment_score": "-0.032375",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.056275",
                    "ticker_sentiment_score": "0.088091",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.222327",
                    "ticker_sentiment_score": "-0.02711",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk, Eli Lilly Stride To Boost Supply Shortage For Newly Found Holy Grail Of Miraculous Weight Loss Drugs - Novo Nordisk  ( NYSE:NVO ) , Eli Lilly  ( NYSE:LLY ) ",
            "url": "https://www.benzinga.com/general/biotech/24/02/37068324/novo-nordisk-eli-lilly-stride-to-boost-supply-shortage-for-newly-found-holy-grail-of-miraculous-w",
            "time_published": "20240212T135745",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "The unprecedented demand for weight loss drugs, including Novo Nordisk A/S's NVO Wegovy and Eli Lilly And Co's LLY Zepbound, has created a supply crunch, leaving patients struggling to access these injectable treatments.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Wegovy_2.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.146812,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.608634",
                    "ticker_sentiment_score": "0.160399",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "CTLT",
                    "relevance_score": "0.169676",
                    "ticker_sentiment_score": "0.130414",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.608634",
                    "ticker_sentiment_score": "0.321378",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "This Unstoppable Growth Stock Just Announced More Good News: Is It a Buy?",
            "url": "https://www.fool.com/investing/2024/02/12/this-unstoppable-growth-stock-just-announced-more/",
            "time_published": "20240212T134500",
            "authors": [
                "Prosper Junior Bakiny"
            ],
            "summary": "The drugmaker continues to impress investors.",
            "banner_image": "https://g.foolcdn.com/editorial/images/764366/doctor-and-patient-talking.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.94762"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.217867,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.449503",
                    "ticker_sentiment_score": "0.281777",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Short sellers boosted by 'Hedge Fund Nirvana' that sees most heavily-shorted companies suffer",
            "url": "https://www.marketwatch.com/story/short-sellers-boosted-by-hedge-fund-nirvana-that-sees-most-heavily-shorted-companies-suffer-5be59096",
            "time_published": "20240212T124700",
            "authors": [
                "Louis Goss"
            ],
            "summary": "The most heavily shorted stocks have underperformed in 2024 compared to rivals, in a turnaround compared to ...",
            "banner_image": "https://images.mktw.net/im-17674986?width=700&height=488",
            "source": "MarketWatch",
            "category_within_source": "Top Stories",
            "source_domain": "www.marketwatch.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.2"
                }
            ],
            "overall_sentiment_score": 0.067078,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "WHR",
                    "relevance_score": "0.19661",
                    "ticker_sentiment_score": "0.055727",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BX",
                    "relevance_score": "0.19661",
                    "ticker_sentiment_score": "0.055727",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "KMI",
                    "relevance_score": "0.19661",
                    "ticker_sentiment_score": "0.055727",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "KR",
                    "relevance_score": "0.19661",
                    "ticker_sentiment_score": "0.055727",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BBY",
                    "relevance_score": "0.19661",
                    "ticker_sentiment_score": "0.055727",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.19661",
                    "ticker_sentiment_score": "0.055727",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AXP",
                    "relevance_score": "0.19661",
                    "ticker_sentiment_score": "0.055727",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MRO",
                    "relevance_score": "0.19661",
                    "ticker_sentiment_score": "0.055727",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MRNA",
                    "relevance_score": "0.19661",
                    "ticker_sentiment_score": "0.055727",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BBWI",
                    "relevance_score": "0.19661",
                    "ticker_sentiment_score": "0.055727",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GE",
                    "relevance_score": "0.19661",
                    "ticker_sentiment_score": "0.055727",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Could Eli Lilly's Zepbound Become the World's Best-Selling Drug?",
            "url": "https://www.fool.com/investing/2024/02/12/could-lillys-zepbound-become-worlds-best-seller/",
            "time_published": "20240212T100300",
            "authors": [
                "Adria Cimino"
            ],
            "summary": "Everyone is excited about Zepbound, from patients to investors...",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F764827%2Fgettyimages-three-investors-look-at-a-computer_in-office.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.938793"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.1742,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "GS",
                    "relevance_score": "0.04531",
                    "ticker_sentiment_score": "0.070678",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.390904",
                    "ticker_sentiment_score": "0.270324",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.04531",
                    "ticker_sentiment_score": "0.070678",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk Is Scaling a Barrier to Growth. Should You Buy Its Stock Now?",
            "url": "https://www.fool.com/investing/2024/02/11/novo-nordisk-is-scaling-a-barrier-to-growth-should/",
            "time_published": "20240211T172500",
            "authors": [
                "Alex Carchidi"
            ],
            "summary": "Even more revenue is on the way from additional sales of Wegovy.",
            "banner_image": "https://g.foolcdn.com/editorial/images/764279/tablet-thinking-office.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.905476"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.839681"
                }
            ],
            "overall_sentiment_score": 0.161313,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.048621",
                    "ticker_sentiment_score": "0.061823",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CTLT",
                    "relevance_score": "0.048621",
                    "ticker_sentiment_score": "0.008959",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.416844",
                    "ticker_sentiment_score": "0.16777",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Could This Warren Buffett Advice Help You Become a Millionaire?",
            "url": "https://www.fool.com/investing/2024/02/11/could-this-buffett-advice-help-you-become-rich/",
            "time_published": "20240211T120100",
            "authors": [
                "Adria Cimino"
            ],
            "summary": "Both experienced and new investors may benefit from this investment...",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F764544%2Fbuffett11-tmf.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.998333"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.25"
                }
            ],
            "overall_sentiment_score": 0.333185,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.060694",
                    "ticker_sentiment_score": "0.032999",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.060694",
                    "ticker_sentiment_score": "0.032999",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMZN",
                    "relevance_score": "0.060694",
                    "ticker_sentiment_score": "0.032999",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BRK-A",
                    "relevance_score": "0.060694",
                    "ticker_sentiment_score": "0.251183",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Eli Lilly Just Succeeded Where Others Failed, but Does It Matter for the Stock?",
            "url": "https://www.fool.com/investing/2024/02/10/eli-lilly-just-succeeded-where-others-failed-but-d/",
            "time_published": "20240210T163000",
            "authors": [
                "Alex Carchidi"
            ],
            "summary": "Potentially adding billions of dollars in revenue might move the needle for the pharmaceutical giant, but that could take years.",
            "banner_image": "https://g.foolcdn.com/editorial/images/764034/investor-smiles-while-looking-at-tablet-in-airplane.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.538269"
                }
            ],
            "overall_sentiment_score": 0.168402,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.306325",
                    "ticker_sentiment_score": "0.09986",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "3 Stocks That Could Trounce the Market in 2024",
            "url": "https://www.fool.com/investing/2024/02/10/3-stocks-that-could-trounce-the-market-in-2024/",
            "time_published": "20240210T114900",
            "authors": [
                "David Jagielski",
                "and Prosper Junior Bakiny",
                "Keith Speights"
            ],
            "summary": "These stocks appear to have what it takes to beat the market this year.",
            "banner_image": "https://g.foolcdn.com/editorial/images/764580/person-smiling-and-looking-at-laptop.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.413559"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.998932"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.285154,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.196132",
                    "ticker_sentiment_score": "0.143278",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VRTX",
                    "relevance_score": "0.157483",
                    "ticker_sentiment_score": "0.154214",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "GS",
                    "relevance_score": "0.039614",
                    "ticker_sentiment_score": "0.153045",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "CTLT",
                    "relevance_score": "0.039614",
                    "ticker_sentiment_score": "0.096768",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.234307",
                    "ticker_sentiment_score": "0.179938",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "S&P 500 Hits 5,000, Magnificent 7 Tops $13 Trillion, Commercial Real Estate Cracks Emerge: The Week In The Markets - Apple  ( NASDAQ:AAPL ) , Amazon.com  ( NASDAQ:AMZN ) ",
            "url": "https://www.benzinga.com/markets/equities/24/02/37043860/s-p-500-hits-5-000-magnificent-7-tops-13-trillion-commercial-real-estate-cracks-emerge-the-week-",
            "time_published": "20240209T210819",
            "authors": [
                "Piero Cingari"
            ],
            "summary": "The S&P 500 index surged past the 5,000-point threshold by the week's end, setting new record highs on the optimism surrounding artificial intelligence. Both the S&P 500 and the Nasdaq 100 celebrated their 14th positive week out of the last 15, showcasing the resilience of the winter rally.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Wall-Street-.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Markets",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "IPO",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.796627"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.2"
                }
            ],
            "overall_sentiment_score": 0.157472,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.15697",
                    "ticker_sentiment_score": "0.096429",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.379435",
                    "ticker_sentiment_score": "0.252457",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.15697",
                    "ticker_sentiment_score": "0.096429",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AAPL",
                    "relevance_score": "0.15697",
                    "ticker_sentiment_score": "0.096429",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AVGO",
                    "relevance_score": "0.07887",
                    "ticker_sentiment_score": "-0.060031",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.07887",
                    "ticker_sentiment_score": "0.044833",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BRK-A",
                    "relevance_score": "0.07887",
                    "ticker_sentiment_score": "-0.060031",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NYCB",
                    "relevance_score": "0.15697",
                    "ticker_sentiment_score": "-0.090253",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.15697",
                    "ticker_sentiment_score": "0.096429",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.233556",
                    "ticker_sentiment_score": "-0.003743",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.15697",
                    "ticker_sentiment_score": "-0.081232",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CMG",
                    "relevance_score": "0.15697",
                    "ticker_sentiment_score": "0.058219",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMZN",
                    "relevance_score": "0.233556",
                    "ticker_sentiment_score": "0.180448",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "PLTR",
                    "relevance_score": "0.15697",
                    "ticker_sentiment_score": "-0.090253",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PSHZF",
                    "relevance_score": "0.07887",
                    "ticker_sentiment_score": "0.022857",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WMT",
                    "relevance_score": "0.15697",
                    "ticker_sentiment_score": "0.058219",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Why Shares of Eli Lilly Popped This Week",
            "url": "https://www.fool.com/investing/2024/02/09/why-shares-of-eli-lilly-popped-this-week/",
            "time_published": "20240209T193401",
            "authors": [
                "Brett Schafer"
            ],
            "summary": "The pharmaceutical giant is gaining momentum, and investors are excited.",
            "banner_image": "https://media.ycharts.com/charts/6adc7901c4a88659abaceda0365bf270.png",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.995973"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.214378"
                }
            ],
            "overall_sentiment_score": 0.184299,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.733479",
                    "ticker_sentiment_score": "0.295235",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "SPGI",
                    "relevance_score": "0.110462",
                    "ticker_sentiment_score": "0.13519",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "What to think about 'Peak 65'",
            "url": "https://www.marketwatch.com/story/what-to-think-about-peak-65-d23f2413",
            "time_published": "20240209T190600",
            "authors": [
                "Philip van Doorn"
            ],
            "summary": "Also: Strategies to build a retirement nest egg and make it last, and a different way for investors to play the weight-loss-drug craze.",
            "banner_image": "https://images.mktw.net/im-74524387?width=700&height=486",
            "source": "MarketWatch",
            "category_within_source": "Top Stories",
            "source_domain": "www.marketwatch.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.992549"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.714479"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.095345,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "VKTX",
                    "relevance_score": "0.085936",
                    "ticker_sentiment_score": "0.071851",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "C",
                    "relevance_score": "0.04303",
                    "ticker_sentiment_score": "0.012989",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.128592",
                    "ticker_sentiment_score": "-0.025551",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.085936",
                    "ticker_sentiment_score": "-0.062043",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.128592",
                    "ticker_sentiment_score": "0.022061",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WEWOW",
                    "relevance_score": "0.04303",
                    "ticker_sentiment_score": "0.093845",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NYCB",
                    "relevance_score": "0.085936",
                    "ticker_sentiment_score": "-0.045374",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BMY",
                    "relevance_score": "0.085936",
                    "ticker_sentiment_score": "-0.062043",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Pharma Stock Roundup: AZN & LLY's Q4 Earnings, NVO, NVS & MRK's M&A Deals",
            "url": "https://www.zacks.com/stock/news/2224190/pharma-stock-roundup-azn-llys-q4-earnings-nvo-nvs-mrks-ma-deals",
            "time_published": "20240209T153600",
            "authors": [
                "Kinjel Shah"
            ],
            "summary": "Eli Lilly (LLY) and AstraZeneca (AZN) announce fourth-quarter results. Novo Nordisk (NVO), Merck (MRK) and Novartis (NVS) make M&A announcements.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/52/873.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.796627"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.976671"
                },
                {
                    "topic": "Mergers & Acquisitions",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": 0.080745,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.291182",
                    "ticker_sentiment_score": "0.088229",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MOR",
                    "relevance_score": "0.099066",
                    "ticker_sentiment_score": "0.005453",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.244354",
                    "ticker_sentiment_score": "0.109061",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CTLT",
                    "relevance_score": "0.148121",
                    "ticker_sentiment_score": "0.043887",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.291182",
                    "ticker_sentiment_score": "0.037556",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.099066",
                    "ticker_sentiment_score": "-0.074089",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Foghorn  ( FHTX )  Jumps 55% as Lilly Takes Up FHD-909 Development",
            "url": "https://www.zacks.com/stock/news/2224167/foghorn-fhtx-jumps-55-as-lilly-takes-up-fhd-909-development",
            "time_published": "20240209T150200",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Foghorn (FHTX) gains 55% as its strategic collaboration partner, Lilly, selects the pre-clinical candidate, FHD-909, for clinical development.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c3/648.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.938793"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.173802,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.353562",
                    "ticker_sentiment_score": "0.289334",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "FHTX",
                    "relevance_score": "0.28636",
                    "ticker_sentiment_score": "0.213203",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "PBYI",
                    "relevance_score": "0.28636",
                    "ticker_sentiment_score": "0.153793",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Is Tesla Still A Magnificent 7 Stock? Berkshire Hathaway, Broadcom, Eli Lilly Line Up As Contenders - Broadcom  ( NASDAQ:AVGO ) , iShares U.S. Financial Services ETF  ( ARCA:IYG ) ",
            "url": "https://www.benzinga.com/news/earnings/24/02/37035036/is-tesla-still-a-magnificent-7-stock-ev-maker-could-get-bumped-by-these-companies",
            "time_published": "20240209T143835",
            "authors": [
                "Neil Dennis"
            ],
            "summary": "Tesla's TSLA standing within the Magnificent Seven is in question. What Happened: The Austin, Texas-based electric vehicle ( EV ) company now stands at number nine on the list of biggest companies on the S&P 500 index.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/musk-tesla-red-shutter_2.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.967645"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.9545"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.201139,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.108958",
                    "ticker_sentiment_score": "0.475072",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "AVGO",
                    "relevance_score": "0.215894",
                    "ticker_sentiment_score": "0.223963",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "BCS",
                    "relevance_score": "0.108958",
                    "ticker_sentiment_score": "0.102561",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.41627",
                    "ticker_sentiment_score": "-0.002894",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MS",
                    "relevance_score": "0.162802",
                    "ticker_sentiment_score": "0.095426",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BRK-A",
                    "relevance_score": "0.054607",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Philip Johnson to Retire as Lilly Treasurer",
            "url": "https://www.prnewswire.com/news-releases/philip-johnson-to-retire-as-lilly-treasurer-302058585.html",
            "time_published": "20240209T143000",
            "authors": [
                "Eli Lilly and Company"
            ],
            "summary": "INDIANAPOLIS, Feb. 9, 2024 /PRNewswire/ -- Eli Lilly and Company ( NYSE:LLY ) today announced that after more than 28 years, Philip Johnson, group vice president and treasurer, will retire from the company at the end of February to pursue a new professional opportunity.",
            "banner_image": "https://mma.prnewswire.com/media/133140/eli_lilly_and_company_logo.jpg?p=facebook",
            "source": "PR Newswire",
            "category_within_source": "n/a",
            "source_domain": "www.prnewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.310843"
                }
            ],
            "overall_sentiment_score": 0.253815,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.616228",
                    "ticker_sentiment_score": "0.36808",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.077094",
                    "ticker_sentiment_score": "0.146835",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Warren Buffett And Disney Share A $543 Billion Money-Making Secret",
            "url": "https://www.investors.com/etfs-and-funds/sectors/sp500-warren-buffett-and-disney-share-billion-moneymaking-secret/",
            "time_published": "20240209T130000",
            "authors": [
                "MATT KRANTZ",
                "Investor's Business Daily"
            ],
            "summary": "S&P 500: Warren Buffett And Disney Share $543 Billion Moneymaking Secret Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2017/11/Stock-WarrenBuffett-01-shutt.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.266143"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.25"
                }
            ],
            "overall_sentiment_score": 0.4244,
            "overall_sentiment_label": "Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.18967",
                    "ticker_sentiment_score": "0.256351",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "SPGI",
                    "relevance_score": "0.095517",
                    "ticker_sentiment_score": "-0.083961",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AAPL",
                    "relevance_score": "0.18967",
                    "ticker_sentiment_score": "0.398988",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "IBKR",
                    "relevance_score": "0.18967",
                    "ticker_sentiment_score": "0.165025",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.18967",
                    "ticker_sentiment_score": "0.398988",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "BRK-A",
                    "relevance_score": "0.281153",
                    "ticker_sentiment_score": "0.312127",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Is Eli Lilly Stock a Buy Now?",
            "url": "https://www.fool.com/investing/2024/02/09/is-eli-lilly-stock-a-buy-now/",
            "time_published": "20240209T121500",
            "authors": [
                "David Jagielski"
            ],
            "summary": "Eli Lilly's valuation is approaching $700 billion.",
            "banner_image": "https://g.foolcdn.com/editorial/images/764145/person-reviewing-a-sample-in-a-lab.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.988915"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.365926"
                }
            ],
            "overall_sentiment_score": 0.102609,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.726705",
                    "ticker_sentiment_score": "0.150642",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Zacks Market Edge Highlights: NVDA, LLY, CMG, DECK and VRT",
            "url": "https://www.zacks.com/stock/news/2223834/zacks-market-edge-highlights-nvda-lly-cmg-deck-and-vrt",
            "time_published": "20240209T110000",
            "authors": [
                "Zacks Investment Research"
            ],
            "summary": "NVDA, LLY, CMG, DECK and VRT have been highlighted in this Market Edge article.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/93/534.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.999612"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.998626"
                }
            ],
            "overall_sentiment_score": 0.208369,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.26224",
                    "ticker_sentiment_score": "0.191647",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.312158",
                    "ticker_sentiment_score": "0.116942",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VRT",
                    "relevance_score": "0.407844",
                    "ticker_sentiment_score": "0.17501",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "CMG",
                    "relevance_score": "0.211191",
                    "ticker_sentiment_score": "0.143426",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DECK",
                    "relevance_score": "0.26224",
                    "ticker_sentiment_score": "0.315243",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Jim Cramer Says Investors Should Look Beyond Apple, Meta And Other Magnificent 7 Stocks: 'You Might Be Missing Out On Some Huge Gains' - Apple  ( NASDAQ:AAPL ) , Amazon.com  ( NASDAQ:AMZN ) ",
            "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/02/37024300/jim-cramer-says-investors-should-look-beyond-apple-meta-and-other-magnificent-7-sto",
            "time_published": "20240209T023401",
            "authors": [
                "Benzinga Neuro"
            ],
            "summary": "Jim Cramer, the host of CNBC's \"Mad Money,\" has suggested that investors should look beyond the Magnificent Seven tech stocks for potential high-yield investments.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Jim-Cramer-Photo-by-a-katz-on-Shuttersto_2.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Trading",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.918141"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.25"
                }
            ],
            "overall_sentiment_score": 0.190571,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.167322",
                    "ticker_sentiment_score": "0.103261",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.167322",
                    "ticker_sentiment_score": "0.103261",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.167322",
                    "ticker_sentiment_score": "0.103261",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.167322",
                    "ticker_sentiment_score": "0.103261",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AAPL",
                    "relevance_score": "0.167322",
                    "ticker_sentiment_score": "0.103261",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.327366",
                    "ticker_sentiment_score": "0.231799",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "XPO",
                    "relevance_score": "0.167322",
                    "ticker_sentiment_score": "0.045091",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.167322",
                    "ticker_sentiment_score": "0.176937",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "RGNX",
                    "relevance_score": "0.167322",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WMS",
                    "relevance_score": "0.167322",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Stock Market Hits Highs As AI Plays Skyrocket: Weekly Review",
            "url": "https://www.investors.com/news/stock-market-hits-highs-as-arm-palantir-cloudflare-skyrocket/",
            "time_published": "20240209T001300",
            "authors": [
                "IBD STAFF",
                "Investor's Business Daily"
            ],
            "summary": "The stock market rally generally advanced with the S&P 500 hitting 5,000 for the first time and the Nasdaq at its best levels in over two years. The Dow Jones held just below its all-time highs while the Russell 2000 rebounded back above key levels.",
            "banner_image": "https://www.investors.com/wp-content/uploads/2024/01/Stock-colorfullightbulb-generatedai-01-adobe.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Economy - Fiscal",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.980922"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Real Estate & Construction",
                    "relevance_score": "0.166667"
                }
            ],
            "overall_sentiment_score": 0.088082,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "MDNDF",
                    "relevance_score": "0.017902",
                    "ticker_sentiment_score": "-0.147329",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TEX",
                    "relevance_score": "0.053669",
                    "ticker_sentiment_score": "0.066999",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NBIX",
                    "relevance_score": "0.035794",
                    "ticker_sentiment_score": "0.051683",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "RPD",
                    "relevance_score": "0.053669",
                    "ticker_sentiment_score": "-0.012012",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "EXPE",
                    "relevance_score": "0.053669",
                    "ticker_sentiment_score": "0.049042",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CVGI",
                    "relevance_score": "0.017902",
                    "ticker_sentiment_score": "0.067321",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMGN",
                    "relevance_score": "0.071517",
                    "ticker_sentiment_score": "0.053795",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ARCB",
                    "relevance_score": "0.071517",
                    "ticker_sentiment_score": "0.054344",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DT",
                    "relevance_score": "0.035794",
                    "ticker_sentiment_score": "-0.078802",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.035794",
                    "ticker_sentiment_score": "0.069261",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "QLYS",
                    "relevance_score": "0.053669",
                    "ticker_sentiment_score": "-0.004005",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "HLT",
                    "relevance_score": "0.035794",
                    "ticker_sentiment_score": "0.048215",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CRUS",
                    "relevance_score": "0.035794",
                    "ticker_sentiment_score": "0.09861",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ORLY",
                    "relevance_score": "0.035794",
                    "ticker_sentiment_score": "-0.129876",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.089328",
                    "ticker_sentiment_score": "0.118465",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AOSL",
                    "relevance_score": "0.035794",
                    "ticker_sentiment_score": "0.09861",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CYBR",
                    "relevance_score": "0.035794",
                    "ticker_sentiment_score": "-0.101404",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "RBLX",
                    "relevance_score": "0.035794",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PINS",
                    "relevance_score": "0.053669",
                    "ticker_sentiment_score": "-0.224249",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "CMG",
                    "relevance_score": "0.035794",
                    "ticker_sentiment_score": "-0.158803",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "UBER",
                    "relevance_score": "0.035794",
                    "ticker_sentiment_score": "-0.016619",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "HMC",
                    "relevance_score": "0.035794",
                    "ticker_sentiment_score": "0.072035",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BABA",
                    "relevance_score": "0.035794",
                    "ticker_sentiment_score": "-0.07722",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PYPL",
                    "relevance_score": "0.035794",
                    "ticker_sentiment_score": "0.037818",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SPOT",
                    "relevance_score": "0.035794",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GM",
                    "relevance_score": "0.035794",
                    "ticker_sentiment_score": "0.072035",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NXPI",
                    "relevance_score": "0.035794",
                    "ticker_sentiment_score": "0.09861",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VRTX",
                    "relevance_score": "0.035794",
                    "ticker_sentiment_score": "0.051683",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "RMBS",
                    "relevance_score": "0.035794",
                    "ticker_sentiment_score": "0.09861",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "INTA",
                    "relevance_score": "0.035794",
                    "ticker_sentiment_score": "-0.151575",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "YUM",
                    "relevance_score": "0.035794",
                    "ticker_sentiment_score": "-0.158803",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "FTNT",
                    "relevance_score": "0.053669",
                    "ticker_sentiment_score": "-0.074739",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PI",
                    "relevance_score": "0.035794",
                    "ticker_sentiment_score": "0.09861",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DIOD",
                    "relevance_score": "0.035794",
                    "ticker_sentiment_score": "0.09861",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GILD",
                    "relevance_score": "0.035794",
                    "ticker_sentiment_score": "0.051683",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ARM",
                    "relevance_score": "0.071517",
                    "ticker_sentiment_score": "0.07345",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NET",
                    "relevance_score": "0.035794",
                    "ticker_sentiment_score": "0.018656",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AFRM",
                    "relevance_score": "0.035794",
                    "ticker_sentiment_score": "0.037818",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "As tech layoffs mount, support groups on LinkedIn are helping workers find jobs",
            "url": "https://www.marketwatch.com/story/as-tech-layoffs-mount-communities-on-linkedin-are-trying-to-find-jobs-for-affected-workers-f8248c63",
            "time_published": "20240208T223600",
            "authors": [
                "James Rogers"
            ],
            "summary": "\"People will cross-post opportunities within the group that they believe others could benefit from, people in the group are keen to share opportunities for others.\" ...",
            "banner_image": "https://images.mktw.net/im-61045217/social",
            "source": "MarketWatch",
            "category_within_source": "Top Stories",
            "source_domain": "www.marketwatch.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.097431,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.073886",
                    "ticker_sentiment_score": "0.013266",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ZBH",
                    "relevance_score": "0.073886",
                    "ticker_sentiment_score": "0.009091",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "OKTA",
                    "relevance_score": "0.073886",
                    "ticker_sentiment_score": "-0.075579",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SNAP",
                    "relevance_score": "0.073886",
                    "ticker_sentiment_score": "-0.075579",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.073886",
                    "ticker_sentiment_score": "0.013266",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "RYCEF",
                    "relevance_score": "0.036983",
                    "ticker_sentiment_score": "0.008631",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "EBAY",
                    "relevance_score": "0.073886",
                    "ticker_sentiment_score": "-0.075579",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "U",
                    "relevance_score": "0.073886",
                    "ticker_sentiment_score": "-0.075579",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.073886",
                    "ticker_sentiment_score": "0.070117",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "INFY",
                    "relevance_score": "0.036983",
                    "ticker_sentiment_score": "0.019914",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DOCU",
                    "relevance_score": "0.073886",
                    "ticker_sentiment_score": "-0.075579",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMZN",
                    "relevance_score": "0.110632",
                    "ticker_sentiment_score": "-0.087675",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WMT",
                    "relevance_score": "0.073886",
                    "ticker_sentiment_score": "0.070117",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "XRX",
                    "relevance_score": "0.110632",
                    "ticker_sentiment_score": "-0.095389",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Here's Why Merck, Eli Lilly, and Novo Nordisk Stocks Rose 11% Last Month",
            "url": "https://www.fool.com/investing/2024/02/08/heres-why-merck-eli-lilly-and-novo-nordisk-stocks/",
            "time_published": "20240208T215600",
            "authors": [
                "Ryan Downie"
            ],
            "summary": "Investors are still excited about obesity treatments and weight-management drugs.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F764656%2Fgettyimages-663845678-600x400-bf06395.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.928769"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.238796,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.399506",
                    "ticker_sentiment_score": "0.12975",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SPGI",
                    "relevance_score": "0.059636",
                    "ticker_sentiment_score": "0.101",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "HARP",
                    "relevance_score": "0.11894",
                    "ticker_sentiment_score": "0.227826",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.177584",
                    "ticker_sentiment_score": "0.195563",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Viking Therapeutics may offer investors a cheap entry to the weight-loss drug craze",
            "url": "https://www.marketwatch.com/story/viking-therapeutics-may-offer-investors-a-cheap-entry-to-the-weight-loss-drug-craze-8d5d623a",
            "time_published": "20240208T191800",
            "authors": [
                "Ciara Linnane"
            ],
            "summary": "Stock is trading at $28 compared with Eli Lilly's $739 price tag. That could change if a trial of a pill version of its GLP-1 drug proves effective.",
            "banner_image": "https://images.mktw.net/im-832731/social",
            "source": "MarketWatch",
            "category_within_source": "Top Stories",
            "source_domain": "www.marketwatch.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.451494"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.266143"
                }
            ],
            "overall_sentiment_score": 0.196705,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.204072",
                    "ticker_sentiment_score": "0.306761",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "VKTX",
                    "relevance_score": "0.204072",
                    "ticker_sentiment_score": "0.158504",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.136888",
                    "ticker_sentiment_score": "0.218866",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Should You Buy a Stock on its All-Time Highs?",
            "url": "https://www.zacks.com/stock/news/2223610/should-you-buy-a-stock-on-its-all-time-highs",
            "time_published": "20240208T171800",
            "authors": [
                "Tracey Ryniec"
            ],
            "summary": "There is a stock you love but it's red hot and has gone vertical. Do you dive in or wait for a sell-off?",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/98/53604.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.977154"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.998626"
                }
            ],
            "overall_sentiment_score": 0.197259,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.293741",
                    "ticker_sentiment_score": "0.209306",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.348919",
                    "ticker_sentiment_score": "0.127529",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VRT",
                    "relevance_score": "0.453501",
                    "ticker_sentiment_score": "0.188051",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "CMG",
                    "relevance_score": "0.236972",
                    "ticker_sentiment_score": "0.157067",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "DECK",
                    "relevance_score": "0.293741",
                    "ticker_sentiment_score": "0.343094",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Why Foghorn Therapeutics  ( FHTX )  Stock Is Exploding Higher - Foghorn Therapeutics  ( NASDAQ:FHTX ) ",
            "url": "https://www.benzinga.com/news/24/02/37012990/why-foghorn-therapeutics-fhtx-stock-is-exploding-higher",
            "time_published": "20240208T164828",
            "authors": [
                "Henry Khederian"
            ],
            "summary": "Foghorn Therapeutics Inc. FHTX shares are trading higher by 44.8% to $4.52 during Thursday's session after the company announced that Eli Lilly And Co LLY has chosen FHD-909, an oral BRM selective inhibitor, for clinical development. Foghorn says the drug targets BRG1 mutated non-small cell lung ...",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/doctor-2568481_0.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "News",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.316726"
                }
            ],
            "overall_sentiment_score": 0.029067,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.348919",
                    "ticker_sentiment_score": "0.291555",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "FHTX",
                    "relevance_score": "0.634282",
                    "ticker_sentiment_score": "0.112111",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MS",
                    "relevance_score": "0.11983",
                    "ticker_sentiment_score": "-0.132549",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "The Obesity Drug Update That Sent This Lilly Rival To A Record High",
            "url": "https://www.investors.com/news/technology/vktx-stock-charges-to-a-record-high-on-an-update-for-its-lilly-rivaling-obesity-treatment/",
            "time_published": "20240208T154000",
            "authors": [
                "Investor's Business Daily",
                "ALLISON GATLIN"
            ],
            "summary": "VKTX Stock Charges To A Record High On An Update For Its Lilly-Rivaling Obesity Treatment Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2021/03/Stock-DrugsPills-14-adobe.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.990999"
                }
            ],
            "overall_sentiment_score": 0.164289,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.204647",
                    "ticker_sentiment_score": "-0.048648",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MDGL",
                    "relevance_score": "0.137278",
                    "ticker_sentiment_score": "0.159429",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "VKTX",
                    "relevance_score": "0.563489",
                    "ticker_sentiment_score": "0.487709",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "CYTK",
                    "relevance_score": "0.068896",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DSSMY",
                    "relevance_score": "0.270523",
                    "ticker_sentiment_score": "0.110119",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "What's Going On With Eli Lilly Stock Stock Today? - Eli Lilly  ( NYSE:LLY ) ",
            "url": "https://www.benzinga.com/general/biotech/24/02/37011034/whats-going-on-eli-lilly-stock-thursday",
            "time_published": "20240208T153658",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "Since Monday, Eli Lilly And Co LLY shares have gained 8%, closing at $724.85 on Wednesday, sending the market capitalization to a whopping $690 billion ( roughly ) . Thursday, shares are trading with a session volume of 25.301K compared to an average volume of 3.277 million, as per data from ...",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Eli-Lilly_3.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.77141"
                }
            ],
            "overall_sentiment_score": 0.082912,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.753715",
                    "ticker_sentiment_score": "0.253242",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "BCS",
                    "relevance_score": "0.115232",
                    "ticker_sentiment_score": "-0.179932",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "WFC",
                    "relevance_score": "0.115232",
                    "ticker_sentiment_score": "-0.192315",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "MS",
                    "relevance_score": "0.115232",
                    "ticker_sentiment_score": "-0.179932",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.228073",
                    "ticker_sentiment_score": "-0.172805",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "SNY",
                    "relevance_score": "0.228073",
                    "ticker_sentiment_score": "-0.172805",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                }
            ]
        },
        {
            "title": "4 Reasons Why 2024 Could Be Eli Lilly's Worst Year for the Rest of This Decade",
            "url": "https://www.fool.com/investing/2024/02/08/4-reasons-why-2024-could-be-eli-lillys-worst-year/",
            "time_published": "20240208T105000",
            "authors": [
                "Keith Speights"
            ],
            "summary": "Lilly's headwinds in 2024 should only be temporary challenges.",
            "banner_image": "https://g.foolcdn.com/editorial/images/764351/ozempic.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.796627"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.139906,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.665529",
                    "ticker_sentiment_score": "0.343664",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Apple, Chipotle And Eli Lilly Stocks Baffle Jim Cramer With Unusual Moves: 'Authentic Stupidity Is A Perfectly Plausible Explanation' - Apple  ( NASDAQ:AAPL ) , Chipotle Mexican Grill  ( NYSE:CMG ) ",
            "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/02/36997732/apple-chipotle-and-eli-lilly-stocks-baffle-jim-cramer-with-recent-unusual-movements",
            "time_published": "20240208T020536",
            "authors": [
                "Benzinga Neuro"
            ],
            "summary": "Jim Cramer, the host of CNBC's \"Mad Money,\" expressed skepticism regarding the recent market movements of Apple Inc AAPL, Chipotle Mexican Grill, Inc. CMG, and Eli Lilly And Co LLY.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/jim-cramer-shutterstock_10.png?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Markets",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.316726"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.682689"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.048811,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "CMG",
                    "relevance_score": "0.345674",
                    "ticker_sentiment_score": "-0.10424",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.262994",
                    "ticker_sentiment_score": "-0.04475",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AAPL",
                    "relevance_score": "0.345674",
                    "ticker_sentiment_score": "0.120584",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Triple Threat Of Key Reversals: Warning Shots Fired In High Fliers Nvidia, Eli Lilly, Super Micro Computers - NVIDIA  ( NASDAQ:NVDA ) , Eli Lilly  ( NYSE:LLY ) ",
            "url": "https://www.benzinga.com/trading-ideas/technicals/24/02/36964497/triple-threat-of-key-reversals-warning-shots-fired-in-3-high-fliers",
            "time_published": "20240207T234520",
            "authors": [
                "Aaron Bry"
            ],
            "summary": "In a potential warning sign to investors, three high-flying stocks had key reversals on Tuesday. This means the stocks opened to new highs before trading below their previous closing price.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/02/07/market.man_.up_.shutterstock_139983946.jpg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.413559"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.183233,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.495015",
                    "ticker_sentiment_score": "0.348391",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.817578",
                    "ticker_sentiment_score": "0.414446",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "SMCI",
                    "relevance_score": "0.495015",
                    "ticker_sentiment_score": "0.398493",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Analysts Boost Eli Lilly's Forecast With High Hopes On Mounjaro, Zepbound Performance - Eli Lilly  ( NYSE:LLY ) ",
            "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/02/36990258/analysts-boost-eli-lillys-forecast-with-high-hopes-on-mounjaro-zepbound-performance",
            "time_published": "20240207T194942",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "Tuesday, Eli Lilly And Co LLY reported fourth-quarter of 2023 revenue of $9.35 billion, up 28% Y/Y, beating the consensus of $8.93 billion driven by increases of 16% due to higher realized prices, 11% in volume, and 1% from the favorable impact of foreign exchange rates.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/mounjaro-medication-for-weight-loss_3.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.495866"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.796627"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.155368,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.448316",
                    "ticker_sentiment_score": "0.09135",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MS",
                    "relevance_score": "0.094762",
                    "ticker_sentiment_score": "0.060669",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Abbott Laboratories Stock Getting Closer To Key Technical Benchmark",
            "url": "https://www.investors.com/news/abbott-laboratories-getting-closer-to-key-technical-benchmark/",
            "time_published": "20240207T161100",
            "authors": [
                "GLENN LARKIN",
                "INVESTOR'S BUSINESS DAILY",
                "Investor's Business Daily"
            ],
            "summary": "In a welcome move, Abbott Laboratories ( ABT ) saw its Relative Strength Rating improve from 67 to 73 on Wednesday. When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.",
            "banner_image": "https://www.investors.com/wp-content/uploads/2017/05/IRU4.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.614606"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.214378"
                }
            ],
            "overall_sentiment_score": 0.371044,
            "overall_sentiment_label": "Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.250386",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ABT",
                    "relevance_score": "0.661658",
                    "ticker_sentiment_score": "0.346743",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "ETFs to Buy as Mounjaro Powers Eli Lilly's Q4 Earnings Beat",
            "url": "https://www.zacks.com/stock/news/2222669/etfs-to-buy-as-mounjaro-powers-eli-lillys-q4-earnings-beat",
            "time_published": "20240207T150500",
            "authors": [
                "Sweta Killa"
            ],
            "summary": "Eli Lilly and Company (LLY) posted robust fourth-quarter 2023 earnings, beating estimates on both the top and bottom lines driven by strong sales of its diabetes and weight-loss treatments.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/588.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.947132"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.999965"
                }
            ],
            "overall_sentiment_score": 0.229502,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.337427",
                    "ticker_sentiment_score": "0.312048",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Market Whales and Their Recent Bets on LLY Options - Eli Lilly  ( NYSE:LLY ) ",
            "url": "https://www.benzinga.com/insights/options/24/02/36982491/market-whales-and-their-recent-bets-on-lly-options",
            "time_published": "20240207T144556",
            "authors": [
                "Benzinga Insights"
            ],
            "summary": "Investors with a lot of money to spend have taken a bearish stance on Eli Lilly LLY. We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Markets",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.365926"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": -0.009605,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.702434",
                    "ticker_sentiment_score": "-0.173123",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "WFC",
                    "relevance_score": "0.165031",
                    "ticker_sentiment_score": "-0.15371",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                }
            ]
        },
        {
            "title": "Eli Lilly Earns IBD Stock Rating Upgrade",
            "url": "https://www.investors.com/ibd-data-stories/eli-lilly-earns-ibd-stock-rating-upgrade/",
            "time_published": "20240207T080000",
            "authors": [
                "Investor's Business Daily",
                "INVESTOR'S BUSINESS DAILY"
            ],
            "summary": "On Wednesday, Eli Lilly ( LLY ) got an upgrade for its IBD SmartSelect Composite Rating from 90 to 96. X The new score means the company is now outperforming 96% of all stocks in terms of the most important fundamental and technical stock-picking criteria.",
            "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.818451"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                }
            ],
            "overall_sentiment_score": 0.225151,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.666827",
                    "ticker_sentiment_score": "-0.116293",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Abbott Laboratories Getting Closer To Key Technical Benchmark",
            "url": "https://www.investors.com/ibd-data-stories/abbott-laboratories-getting-closer-to-key-technical-benchmark/",
            "time_published": "20240207T080000",
            "authors": [
                "INVESTOR'S BUSINESS DAILY",
                "Investor's Business Daily"
            ],
            "summary": "In a welcome move, Abbott Laboratories ( ABT ) saw its Relative Strength Rating improve from 67 to 73 on Wednesday. When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.",
            "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.744043"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                }
            ],
            "overall_sentiment_score": 0.362319,
            "overall_sentiment_label": "Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.29234",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ABT",
                    "relevance_score": "0.739411",
                    "ticker_sentiment_score": "0.422149",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Eli Lilly  ( LLY )  Q4 2023 Earnings Call Transcript",
            "url": "https://www.fool.com/earnings/call-transcripts/2024/02/06/eli-lilly-lly-q4-2023-earnings-call-transcript/",
            "time_published": "20240207T003018",
            "authors": [
                "Motley Fool Transcribing"
            ],
            "summary": "LLY earnings call for the period ending December 31, 2023.",
            "banner_image": "https://g.foolcdn.com/misc-assets/fool-transcripts-logo.png",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.99999"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Mergers & Acquisitions",
                    "relevance_score": "0.316726"
                },
                {
                    "topic": "Real Estate & Construction",
                    "relevance_score": "0.25"
                }
            ],
            "overall_sentiment_score": 0.255016,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "EVR",
                    "relevance_score": "0.003584",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "C",
                    "relevance_score": "0.003584",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BAC",
                    "relevance_score": "0.003584",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CTLT",
                    "relevance_score": "0.010751",
                    "ticker_sentiment_score": "0.11558",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MS",
                    "relevance_score": "0.003584",
                    "ticker_sentiment_score": "0.058669",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DICE",
                    "relevance_score": "0.003584",
                    "ticker_sentiment_score": "0.116534",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GS",
                    "relevance_score": "0.003584",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BCS",
                    "relevance_score": "0.003584",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WFC",
                    "relevance_score": "0.003584",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AKUS",
                    "relevance_score": "0.003584",
                    "ticker_sentiment_score": "0.128229",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "APG",
                    "relevance_score": "0.007168",
                    "ticker_sentiment_score": "0.073354",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.078717",
                    "ticker_sentiment_score": "0.13047",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SGTX",
                    "relevance_score": "0.003584",
                    "ticker_sentiment_score": "0.116534",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LBTSF",
                    "relevance_score": "0.007168",
                    "ticker_sentiment_score": "0.110952",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FOREX:GBP",
                    "relevance_score": "0.003584",
                    "ticker_sentiment_score": "0.138176",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Amgen's quarterly results top expectations despite Enbrel sales decline",
            "url": "https://www.marketwatch.com/story/amgens-quarterly-results-top-expectations-despite-enbrel-sales-decline-3720269d",
            "time_published": "20240206T214300",
            "authors": [
                "Eleanor Laise"
            ],
            "summary": "Amgen on Tuesday reported fourth quarter profits and sales that topped analyst expectations even as revenues dropped for one of its top-selling drugs.",
            "banner_image": "https://images.mktw.net/im-814193/social",
            "source": "MarketWatch",
            "category_within_source": "Top Stories",
            "source_domain": "www.marketwatch.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.769861"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.023871,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.181819",
                    "ticker_sentiment_score": "0.190188",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AMGN",
                    "relevance_score": "0.578948",
                    "ticker_sentiment_score": "0.127919",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Stock Market Today: Higher Close for Stocks, Palantir Soars on AI Optimism",
            "url": "https://www.kiplinger.com/investing/stocks/stock-market-today-higher-close-for-stocks-palantir-soars-on-ai-optimism",
            "time_published": "20240206T211241",
            "authors": [
                "Karee Venema"
            ],
            "summary": "Stocks opened higher Tuesday as investors attempted to look past Federal Reserve Chair Jerome Powell's hawkish appearance on \"60 Minutes.\" However, the main indexes ran out of steam as the session wore on as more central bankers took the wait-and-see route toward rate cuts.",
            "banner_image": "https://cdn.mos.cms.futurecdn.net/HPGpPu8yev3y9BJ9WaSXu7-415-80.jpg",
            "source": "Kiplinger",
            "category_within_source": "n/a",
            "source_domain": "www.kiplinger.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.576289"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.538269"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.980716"
                }
            ],
            "overall_sentiment_score": 0.248,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.213048",
                    "ticker_sentiment_score": "0.29933",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NKE",
                    "relevance_score": "0.142989",
                    "ticker_sentiment_score": "0.349454",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "PLTR",
                    "relevance_score": "0.213048",
                    "ticker_sentiment_score": "0.220181",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "WBA",
                    "relevance_score": "0.142989",
                    "ticker_sentiment_score": "0.349454",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Tech Slides, Chinese Stocks Rebound, New York Community Bancorp Tumbles: What's Driving Markets Tuesday? - Amgen  ( NASDAQ:AMGN ) , BP  ( NYSE:BP ) ",
            "url": "https://www.benzinga.com/markets/equities/24/02/36964052/tech-slides-chinese-stocks-rebound-new-york-community-bancorp-tumbles-whats-driving-markets-tues",
            "time_published": "20240206T192404",
            "authors": [
                "Piero Cingari"
            ],
            "summary": "At noon trading in New York, major equity indices on Wall Street remain directionless as traders evaluate the future course of monetary policy ahead of several speeches by Federal Reserve officials in the days ahead.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Wall-Street_4.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Markets",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.451494"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.961735"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": 0.132785,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "SPOT",
                    "relevance_score": "0.177802",
                    "ticker_sentiment_score": "0.062224",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "F",
                    "relevance_score": "0.177802",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "UBS",
                    "relevance_score": "0.177802",
                    "ticker_sentiment_score": "0.062224",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CCK",
                    "relevance_score": "0.177802",
                    "ticker_sentiment_score": "0.062224",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "IVZ",
                    "relevance_score": "0.089462",
                    "ticker_sentiment_score": "0.130458",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SNAP",
                    "relevance_score": "0.177802",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMGN",
                    "relevance_score": "0.177802",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NYCB",
                    "relevance_score": "0.177802",
                    "ticker_sentiment_score": "-0.143048",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "EW",
                    "relevance_score": "0.177802",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FTNT",
                    "relevance_score": "0.177802",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GEHC",
                    "relevance_score": "0.177802",
                    "ticker_sentiment_score": "0.062224",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.177802",
                    "ticker_sentiment_score": "0.062224",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GILD",
                    "relevance_score": "0.177802",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CMG",
                    "relevance_score": "0.177802",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FMC",
                    "relevance_score": "0.177802",
                    "ticker_sentiment_score": "0.062224",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PLTR",
                    "relevance_score": "0.177802",
                    "ticker_sentiment_score": "0.42926",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Eli Lilly rides the weight-loss-drug wave to a new record high, and is now worth more than $700 billion",
            "url": "https://markets.businessinsider.com/news/stocks/eli-lilly-stock-price-q4-earnings-glp-drugs-700-billion-2024-2",
            "time_published": "20240206T170000",
            "authors": [
                "Matthew Fox"
            ],
            "summary": "Eli Lilly Rides the Weight-Loss-Drug Wave to Record, Hits $700 Billion - Markets Insider ...",
            "banner_image": null,
            "source": "Business Insider",
            "category_within_source": "GoogleRSS",
            "source_domain": "markets.businessinsider.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.266143"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.980509"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.224787,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.555911",
                    "ticker_sentiment_score": "0.347831",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "BRK-A",
                    "relevance_score": "0.061003",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.061003",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Wall Street says Big Tech needs to take a breather after huge run. Here's our take",
            "url": "https://www.cnbc.com/2024/02/06/why-wall-street-analysts-think-big-tech-stocks-will-take-a-breather.html",
            "time_published": "20240206T164237",
            "authors": [
                "Morgan Chittum"
            ],
            "summary": "The Investing Club holds its \"Morning Meeting\" every weekday at 10:20 a.m. ET.",
            "banner_image": "https://image.cnbcfm.com/api/v1/image/107306647-1695737403194-gettyimages-1580864430-AFP_33QR73W.jpeg?v=1702925323&w=600&h=300&vtcrop=y",
            "source": "CNBC",
            "category_within_source": "Top News",
            "source_domain": "www.cnbc.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.938793"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.744043"
                }
            ],
            "overall_sentiment_score": 0.211554,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.270773",
                    "ticker_sentiment_score": "0.181956",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.182506",
                    "ticker_sentiment_score": "0.134213",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.182506",
                    "ticker_sentiment_score": "0.134213",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "C",
                    "relevance_score": "0.09186",
                    "ticker_sentiment_score": "0.095197",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMZN",
                    "relevance_score": "0.182506",
                    "ticker_sentiment_score": "0.134213",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Why Eli Lilly Stock Jumped as Much as 5.1% Today Then Gave Up Its Gains",
            "url": "https://www.fool.com/investing/2024/02/06/why-eli-lilly-stock-jumped-as-much-as-51-today/",
            "time_published": "20240206T164140",
            "authors": [
                "Keith Speights"
            ],
            "summary": "Investors shouldn't worry that Lilly's gains quickly evaporated.",
            "banner_image": "https://g.foolcdn.com/editorial/images/764189/scientists-in-a-lab-monitor-microscope.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.997902"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.245766,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.684999",
                    "ticker_sentiment_score": "0.511454",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Stocks In China Flying, Lifting Sentiment In Stock Markets Across The Globe, AI And Weight Loss Drugs Get Hotter - NVIDIA  ( NASDAQ:NVDA ) ",
            "url": "https://www.benzinga.com/markets/24/02/36960189/stocks-in-china-flying-lifting-sentiment-in-stock-markets-across-the-globe-ai-and-weight-loss-drugs",
            "time_published": "20240206T163135",
            "authors": [
                "The Arora Report"
            ],
            "summary": "To gain an edge, this is what you need to know today. Please click here for an enlarged version of the chart of iShares China Large-Cap ETF FXI. Earlier today, NVIDIA Corp NVDA crossed $700. NVDA is in The Arora Report ZYX Buy Model Portfolio.",
            "banner_image": "https://cdn.benzinga.com/files/regularguy-eth-w9codxtsfts-unsplash_19.jpg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.451494"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.996718"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.310843"
                }
            ],
            "overall_sentiment_score": 0.22034,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.101582",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.101582",
                    "ticker_sentiment_score": "0.197234",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.101582",
                    "ticker_sentiment_score": "0.197234",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.201523",
                    "ticker_sentiment_score": "0.156997",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AAPL",
                    "relevance_score": "0.101582",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.101582",
                    "ticker_sentiment_score": "-0.238309",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.151858",
                    "ticker_sentiment_score": "0.017067",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "IVZ",
                    "relevance_score": "0.050894",
                    "ticker_sentiment_score": "0.247528",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "CRYPTO:BTC",
                    "relevance_score": "0.101582",
                    "ticker_sentiment_score": "0.386374",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Earnings Data Deluge",
            "url": "https://www.zacks.com/stock/news/2221920/earnings-data-deluge",
            "time_published": "20240206T160200",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "We have a big day of stock market information on deck, most of which doesn't happen until after the opening bell rings this morning. We have a full docket of Fed presidents reporting later today, including Cleveland's Loretta Mester, Minneapolis' Neel Kashkari, Boston's Susan Collins and ...",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/588.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.538269"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.838487"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.052206,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "CMG",
                    "relevance_score": "0.203215",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.3007",
                    "ticker_sentiment_score": "0.077165",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SPOT",
                    "relevance_score": "0.3007",
                    "ticker_sentiment_score": "0.074298",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Stock Market Mixed With Dow Jones Pulling Ahead; Palantir Soars After Earnings",
            "url": "https://www.investors.com/market-trend/stock-market-today/stock-market-struggles-dow-jones-leads-nasdaq-palantir-spy-stock/",
            "time_published": "20240206T155300",
            "authors": [
                "Investor's Business Daily",
                "KIMBERLEY KOENIG"
            ],
            "summary": "Stock Market Struggles, Dow Jones Leads, Nasdaq Eases. Palantir Soars Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2023/02/Stock-Palantir-04-shutt.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.990786"
                }
            ],
            "overall_sentiment_score": 0.09589,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.103778",
                    "ticker_sentiment_score": "0.062377",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.103778",
                    "ticker_sentiment_score": "0.111245",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.103778",
                    "ticker_sentiment_score": "0.111245",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AAPL",
                    "relevance_score": "0.103778",
                    "ticker_sentiment_score": "0.062377",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.155118",
                    "ticker_sentiment_score": "0.065084",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SPOT",
                    "relevance_score": "0.155118",
                    "ticker_sentiment_score": "0.009552",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.103778",
                    "ticker_sentiment_score": "0.102795",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CDNS",
                    "relevance_score": "0.051999",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "RMBS",
                    "relevance_score": "0.103778",
                    "ticker_sentiment_score": "-0.132313",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "IVZ",
                    "relevance_score": "0.051999",
                    "ticker_sentiment_score": "0.049031",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DOCU",
                    "relevance_score": "0.155118",
                    "ticker_sentiment_score": "-0.090737",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMZN",
                    "relevance_score": "0.103778",
                    "ticker_sentiment_score": "0.062377",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Eli Lilly  ( LLY )  Q4 Earnings Beat, Mounjaro, Zepbound Drive Sales",
            "url": "https://www.zacks.com/stock/news/2221913/eli-lilly-lly-q4-earnings-beat-mounjaro-zepbound-drive-sales",
            "time_published": "20240206T154800",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Eli Lilly (LLY) beats fourth-quarter estimates for earnings as well as sales. The company issues an upbeat guidance for 2024.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/62/5473.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.999997"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.77141"
                }
            ],
            "overall_sentiment_score": 0.177494,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.337951",
                    "ticker_sentiment_score": "0.152966",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "ARQT",
                    "relevance_score": "0.219099",
                    "ticker_sentiment_score": "0.025828",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.126284",
                    "ticker_sentiment_score": "0.035026",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PBYI",
                    "relevance_score": "0.188437",
                    "ticker_sentiment_score": "0.119642",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Earnings, Fed Speakers Dominate Activity; Lilly Beats, Spotify Misses",
            "url": "https://www.zacks.com/stock/news/2221907/earnings-fed-speakers-dominate-activity-lilly-beats-spotify-misses",
            "time_published": "20240206T154100",
            "authors": [
                "Mark Vickery"
            ],
            "summary": "Investors of Lilly (LLY) are responding to the eye-opening efficacy of obesity drugs Mounjaro and Zepbound.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/4d/60715.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.538269"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.928139"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.054458,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "CMG",
                    "relevance_score": "0.19117",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.283323",
                    "ticker_sentiment_score": "0.069326",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SPOT",
                    "relevance_score": "0.283323",
                    "ticker_sentiment_score": "0.0538",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Chips Vs. Oil: Nvidia Now Outweighs The S&P 500's Entire Energy Sector",
            "url": "https://www.investors.com/news/sp500-chips-vs-oil-nvidia-now-outweighs-the-sp-500s-entire-energy-sector/",
            "time_published": "20240206T150700",
            "authors": [
                "KIT NORTON",
                "Investor's Business Daily"
            ],
            "summary": "With Nvidia ( NVDA ) surging 40% since the end of 2023, hitting a market cap of more than $1.7 trillion on Monday, the tech stock is now valued more than the S&P 500's entire energy sector, which includes Exxon Mobil ( XOM ) and Chevron ( CVX ) .",
            "banner_image": "https://www.investors.com/wp-content/uploads/2021/10/Stock-oilderrick-02-adobe.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.2"
                }
            ],
            "overall_sentiment_score": 0.205955,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.213988",
                    "ticker_sentiment_score": "0.100923",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.213988",
                    "ticker_sentiment_score": "0.100923",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.502693",
                    "ticker_sentiment_score": "0.414369",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "OXY",
                    "relevance_score": "0.213988",
                    "ticker_sentiment_score": "0.225735",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "HAL",
                    "relevance_score": "0.213988",
                    "ticker_sentiment_score": "0.225735",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "CVX",
                    "relevance_score": "0.502693",
                    "ticker_sentiment_score": "0.346431",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "COP",
                    "relevance_score": "0.213988",
                    "ticker_sentiment_score": "0.225735",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "BRK-A",
                    "relevance_score": "0.107978",
                    "ticker_sentiment_score": "0.067306",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "XOM",
                    "relevance_score": "0.412861",
                    "ticker_sentiment_score": "0.306878",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.213988",
                    "ticker_sentiment_score": "0.100923",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SLB",
                    "relevance_score": "0.213988",
                    "ticker_sentiment_score": "0.225735",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Dow Jumps Over 100 Points; Eli Lilly Posts Upbeat Earnings - Agrify  ( NASDAQ:AGFY ) , BioRestorative Therapies  ( NASDAQ:BRTX ) ",
            "url": "https://www.benzinga.com/news/earnings/24/02/36957085/dow-jumps-over-100-points-eli-lilly-posts-upbeat-earnings",
            "time_published": "20240206T145204",
            "authors": [
                "Avi Kapoor"
            ],
            "summary": "U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 100 points on Tuesday. Following the market opening Tuesday, the Dow traded up 0.34% to 38,509.84 while the NASDAQ rose 0.21% to 15,629.82. The S&P 500 also rose, gaining, 0.17% to 4,951.38.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/02/06/image30.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Trading",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "IPO",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.538269"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.744043"
                }
            ],
            "overall_sentiment_score": 0.016939,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVIV",
                    "relevance_score": "0.136888",
                    "ticker_sentiment_score": "0.175165",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AGFY",
                    "relevance_score": "0.204072",
                    "ticker_sentiment_score": "0.311293",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.269776",
                    "ticker_sentiment_score": "0.028824",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SPGI",
                    "relevance_score": "0.136888",
                    "ticker_sentiment_score": "-0.084219",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BRTX",
                    "relevance_score": "0.204072",
                    "ticker_sentiment_score": "-0.044273",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PRSO",
                    "relevance_score": "0.136888",
                    "ticker_sentiment_score": "-0.098739",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SUNW",
                    "relevance_score": "0.204072",
                    "ticker_sentiment_score": "0.248732",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "TENX",
                    "relevance_score": "0.136888",
                    "ticker_sentiment_score": "0.20693",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "CRYPTO:PAY",
                    "relevance_score": "0.068698",
                    "ticker_sentiment_score": "0.166607",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Eli Lilly Soars On Diabetes And Obesity Drug Boom, Projects 20% Revenue Increase In 2024 - Eli Lilly  ( NYSE:LLY ) ",
            "url": "https://www.benzinga.com/markets/equities/24/02/36955955/eli-lilly-soars-on-diabetes-and-obesity-drug-boom-projects-20-revenue-increase-in-2024",
            "time_published": "20240206T141519",
            "authors": [
                "Benzinga Neuro"
            ],
            "summary": "In a recent announcement, Eli Lilly and Co LLY has projected a significant revenue increase for 2024, driven by the demand for its diabetes and obesity drugs. What Happened: The pharmaceutical giant anticipates a 20% rise in sales, propelling its revenues to over $40 billion, reported the ...",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Eli-Lilly_2.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.77141"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.224494,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.345674",
                    "ticker_sentiment_score": "0.253218",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Eli Lilly's stock leaps toward a record as a 16% jump in prices boosted profit",
            "url": "https://www.marketwatch.com/story/eli-lillys-stock-surges-toward-a-5th-straight-record-after-an-earnings-beat-and-upbeat-outlook-5a298405",
            "time_published": "20240206T133200",
            "authors": [
                "Tomi Kilgore"
            ],
            "summary": "U.S. prices for Lilly's drugs climbed 27%, driven by diabetes treatment Mounjaro, while prices outside the U.S. fell.",
            "banner_image": "https://images.mktw.net/im-84642168/social",
            "source": "MarketWatch",
            "category_within_source": "Top Stories",
            "source_domain": "www.marketwatch.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.98396"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.858979"
                }
            ],
            "overall_sentiment_score": 0.168429,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.31482",
                    "ticker_sentiment_score": "0.161944",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Why Is Eli Lilly Stock Trading Higher Today? - Eli Lilly  ( NYSE:LLY ) ",
            "url": "https://www.benzinga.com/general/biotech/24/02/36954087/investors-cheer-highly-awaited-eli-lilly-earnings-q4-performance-surpass-expectations-thanks-to-s",
            "time_published": "20240206T132936",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "Tuesday, Eli Lilly And Co LLY reported fourth-quarter of 2023 revenue of $9.35 billion, up 28% Y/Y, beating the consensus of $8.93 billion driven by increases of 16% due to higher realized prices, 11% in volume, and 1% from the favorable impact of foreign exchange rates.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/mounjaro-medication-for-weight-loss_2.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Trading",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.266143"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.360215"
                }
            ],
            "overall_sentiment_score": 0.074302,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.68732",
                    "ticker_sentiment_score": "-0.019044",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Futures Dip; Palantir Soars On Surging AI Demand",
            "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-fall-palantir-soars-on-surging-ai-demand/",
            "time_published": "20240206T131700",
            "authors": [
                "SCOTT LEHTONEN",
                "Investor's Business Daily"
            ],
            "summary": "Dow Jones Futures Fall As Tesla Slides On Downgrade. Palantir Soars On Surging AI Demand Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2021/09/Stock-wallstreetflag-01-adobe.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.142857"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.142857"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.142857"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.142857"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.142857"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.142857"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.795202"
                },
                {
                    "topic": "Real Estate & Construction",
                    "relevance_score": "0.142857"
                }
            ],
            "overall_sentiment_score": 0.205444,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.157741",
                    "ticker_sentiment_score": "0.110092",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AAPL",
                    "relevance_score": "0.196451",
                    "ticker_sentiment_score": "0.134443",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SPOT",
                    "relevance_score": "0.118647",
                    "ticker_sentiment_score": "0.130868",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "EXPE",
                    "relevance_score": "0.157741",
                    "ticker_sentiment_score": "0.107195",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VRTX",
                    "relevance_score": "0.079261",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MDB",
                    "relevance_score": "0.157741",
                    "ticker_sentiment_score": "0.015246",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "IVZ",
                    "relevance_score": "0.039679",
                    "ticker_sentiment_score": "0.117525",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.118647",
                    "ticker_sentiment_score": "0.081445",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.196451",
                    "ticker_sentiment_score": "0.077388",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LEN",
                    "relevance_score": "0.157741",
                    "ticker_sentiment_score": "0.059783",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.118647",
                    "ticker_sentiment_score": "0.130868",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PLTR",
                    "relevance_score": "0.079261",
                    "ticker_sentiment_score": "-0.054554",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WMT",
                    "relevance_score": "0.157741",
                    "ticker_sentiment_score": "0.008044",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Eli Lilly  ( LLY )  Tops Q4 Earnings and Revenue Estimates",
            "url": "https://www.zacks.com/stock/news/2221562/eli-lilly-lly-tops-q4-earnings-and-revenue-estimates",
            "time_published": "20240206T125503",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Lilly (LLY) delivered earnings and revenue surprises of 0.81% and 5.53%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default145.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.999981"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.266143"
                }
            ],
            "overall_sentiment_score": 0.144094,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.399204",
                    "ticker_sentiment_score": "0.207635",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "ARDX",
                    "relevance_score": "0.138464",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "S&P, Nasdaq Futures Point To Another Day Of Weakness: What's Going On With Stocks? - Invesco QQQ Trust, Series 1  ( NASDAQ:QQQ ) , SPDR S&P 500  ( ARCA:SPY ) ",
            "url": "https://www.benzinga.com/news/earnings/24/02/36952531/us-stocks-brace-for-another-day-in-the-red-as-rally-loses-steam-analyst-sees-market-pullback-on-thi",
            "time_published": "20240206T123737",
            "authors": [
                "Shanthi Rexaline"
            ],
            "summary": "U.S. stocks are poised for another day of weakness, although some positive tech earnings may provide a modest lift to the sector. The market appears to be digesting information following a rally that began after the early January downturn.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/nyse-shutter_4.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Trading",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.682689"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.99676"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.928139"
                }
            ],
            "overall_sentiment_score": -0.024063,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "DD",
                    "relevance_score": "0.091162",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MSTR",
                    "relevance_score": "0.091162",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SPOT",
                    "relevance_score": "0.091162",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "F",
                    "relevance_score": "0.091162",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "RMBS",
                    "relevance_score": "0.091162",
                    "ticker_sentiment_score": "-0.208732",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "IVZ",
                    "relevance_score": "0.045655",
                    "ticker_sentiment_score": "0.212156",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AMGN",
                    "relevance_score": "0.091162",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "HTZ",
                    "relevance_score": "0.091162",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JJSF",
                    "relevance_score": "0.091162",
                    "ticker_sentiment_score": "-0.348877",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "CRUS",
                    "relevance_score": "0.091162",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "EW",
                    "relevance_score": "0.091162",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CHKP",
                    "relevance_score": "0.091162",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CMA",
                    "relevance_score": "0.045655",
                    "ticker_sentiment_score": "-0.132222",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GEHC",
                    "relevance_score": "0.091162",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.091162",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "HRB",
                    "relevance_score": "0.091162",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LPLA",
                    "relevance_score": "0.045655",
                    "ticker_sentiment_score": "0.176076",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "YUMC",
                    "relevance_score": "0.091162",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CMG",
                    "relevance_score": "0.091162",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SQ",
                    "relevance_score": "0.045655",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WU",
                    "relevance_score": "0.091162",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PLTR",
                    "relevance_score": "0.091162",
                    "ticker_sentiment_score": "0.309859",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Eli Lilly Veers Higher On Fourth-Quarter Beat",
            "url": "https://www.investors.com/news/technology/eli-lilly-stock-eli-lilly-earnings-q4-2023/",
            "time_published": "20240206T123200",
            "authors": [
                "ALLISON GATLIN",
                "Investor's Business Daily"
            ],
            "summary": "Eli Lilly ( LLY ) stock jetted higher early Tuesday after the pharmaceutical company reported adjusted profit of $2.49 per share on $9.35 billion in fourth-quarter sales. On average, analysts surveyed by FactSet expected Lilly to earn $2.30 per share on $8.95 billion in sales.",
            "banner_image": "https://www.investors.com/wp-content/uploads/2018/04/stock-Eli-Lilly-01-company.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.682689"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.929393"
                }
            ],
            "overall_sentiment_score": 0.232148,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.941495",
                    "ticker_sentiment_score": "0.411227",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Lilly Reports Strong Fourth-Quarter 2023 Financial Results and Provides 2024 Guidance",
            "url": "https://www.prnewswire.com/news-releases/lilly-reports-strong-fourth-quarter-2023-financial-results-and-provides-2024-guidance-302053915.html",
            "time_published": "20240206T114500",
            "authors": [
                "Eli Lilly and Company"
            ],
            "summary": "( i ) Lilly defines New Products as select products launched since 2022, which currently consist of Ebglyss, Jaypirca, Mounjaro, Omvoh and Zepbound. ( ii ) Lilly defines Growth Products as select products launched prior to 2022, which currently consist of Cyramza, Emgality, Jardiance, Olumiant, ...",
            "banner_image": "https://mma.prnewswire.com/media/133140/eli_lilly_and_company_logo.jpg?p=facebook",
            "source": "PR Newswire",
            "category_within_source": "n/a",
            "source_domain": "www.prnewswire.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.999998"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Mergers & Acquisitions",
                    "relevance_score": "0.316726"
                }
            ],
            "overall_sentiment_score": 0.145433,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "BEAM",
                    "relevance_score": "0.01102",
                    "ticker_sentiment_score": "-0.072984",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.331478",
                    "ticker_sentiment_score": "0.17446",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "CURN",
                    "relevance_score": "0.01102",
                    "ticker_sentiment_score": "-0.014773",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AKUS",
                    "relevance_score": "0.01102",
                    "ticker_sentiment_score": "0.118355",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "The first Wall Street bank to make a recession call now expects a narrow landing",
            "url": "https://www.marketwatch.com/story/the-first-wall-street-bank-to-make-a-recession-call-now-expects-a-narrow-landing-660b7549",
            "time_published": "20240206T114000",
            "authors": [
                "Barbara Kollmeyer"
            ],
            "summary": "The U.S. economy will land on a \"narrow path\" this year, and avoid a recession, thanks in part to a better consumer picture, says Deutsche Bank.",
            "banner_image": "https://images.mktw.net/im-54030136?width=700&height=559",
            "source": "MarketWatch",
            "category_within_source": "Top Stories",
            "source_domain": "www.marketwatch.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.451494"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.977154"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.067508,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "BABA",
                    "relevance_score": "0.087985",
                    "ticker_sentiment_score": "0.138488",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SPOT",
                    "relevance_score": "0.04406",
                    "ticker_sentiment_score": "0.047851",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.087985",
                    "ticker_sentiment_score": "-0.073181",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CMG",
                    "relevance_score": "0.087985",
                    "ticker_sentiment_score": "-0.073181",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LRLCF",
                    "relevance_score": "0.04406",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMGN",
                    "relevance_score": "0.087985",
                    "ticker_sentiment_score": "-0.073181",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PLTR",
                    "relevance_score": "0.087985",
                    "ticker_sentiment_score": "-0.093878",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Ford, Eli Lilly And 3 Stocks To Watch Heading Into Tuesday - Ford Motor  ( NYSE:F ) , Eli Lilly  ( NYSE:LLY ) ",
            "url": "https://www.benzinga.com/news/earnings/24/02/36947833/ford-eli-lilly-and-3-stocks-to-watch-heading-into-tuesday",
            "time_published": "20240206T070649",
            "authors": [
                "Avi Kapoor"
            ],
            "summary": "With U.S. stock futures trading mixed this morning on Tuesday, some of the stocks that may grab investor focus today are as follows: Wall Street expects Eli Lilly and Company LLY to report quarterly earnings at $2.19 per share on revenue of $8.93 billion before the opening bell, according to data ...",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/02/06/ford_-_logo.jpg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Trading",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.413559"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.972476"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.268213,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.47672",
                    "ticker_sentiment_score": "0.412575",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "AMKR",
                    "relevance_score": "0.47672",
                    "ticker_sentiment_score": "-0.180827",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "CMI",
                    "relevance_score": "0.47672",
                    "ticker_sentiment_score": "0.32771",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "F",
                    "relevance_score": "0.329551",
                    "ticker_sentiment_score": "0.438952",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "NXPI",
                    "relevance_score": "0.47672",
                    "ticker_sentiment_score": "0.676595",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Eli Lilly Likely To Report Higher Q4 Earnings; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts - Eli Lilly  ( NYSE:LLY ) ",
            "url": "https://www.benzinga.com/news/earnings/24/02/36947735/eli-lilly-likely-to-report-higher-q4-earnings-here-are-the-recent-forecast-changes-from-wall-street",
            "time_published": "20240206T060540",
            "authors": [
                "Avi Kapoor"
            ],
            "summary": "Eli Lilly and Company LLY is expected to release earnings results for its fourth quarter, before the opening bell on Feb. 6, 2024. Analysts expect the company to report quarterly earnings at $2.19 per share, up from year-ago earnings of $2.09 per share.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/02/06/eli_lilly_-_logo.jpg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Trading",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.796627"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.714479"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.049154,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.390904",
                    "ticker_sentiment_score": "0.162099",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "C",
                    "relevance_score": "0.135347",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WFC",
                    "relevance_score": "0.135347",
                    "ticker_sentiment_score": "-0.098155",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MS",
                    "relevance_score": "0.135347",
                    "ticker_sentiment_score": "-0.016125",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "PLTR, NVDA, LLY, SYM, TSLA: Top 5 Trending Stocks Today - NVIDIA  ( NASDAQ:NVDA ) , Eli Lilly  ( NYSE:LLY ) ",
            "url": "https://www.benzinga.com/markets/equities/24/02/36946343/palantir-nvidia-eli-lilly-symbotic-tesla-why-these-5-stocks-are-on-investors-radars-today",
            "time_published": "20240206T014514",
            "authors": [
                "Benzinga Neuro"
            ],
            "summary": "U.S. stocks traded lower at the end of trading on Monday with the Dow Jones Industrial Average declining 0.7% to 38,380.12 and the S&P 500 dropping 0.3% to 4,942.81. The Nasdaq ended Monday lower by 0.2% at 15,597.68. These are the top stocks that gained the attention of retail traders and ...",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Stocks-Photo-by-Phongphan-on-Shutterstoc_7.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Markets",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Economy - Fiscal",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.266143"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.796627"
                }
            ],
            "overall_sentiment_score": 0.287582,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.163354",
                    "ticker_sentiment_score": "0.191244",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.24289",
                    "ticker_sentiment_score": "0.47824",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.24289",
                    "ticker_sentiment_score": "-0.095762",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GS",
                    "relevance_score": "0.082111",
                    "ticker_sentiment_score": "0.285316",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "SYM",
                    "relevance_score": "0.163354",
                    "ticker_sentiment_score": "0.297278",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "PLTR",
                    "relevance_score": "0.163354",
                    "ticker_sentiment_score": "0.214982",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        }
    ]
}